https://trial.medpath.com/news/3f0d5923e11a20db/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/ee06ca292ac93622/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/6afeb551a9f3789a/che-negatively-impacts-quality-of-life-according-to-patients-dermatology-times 2024-11-04T14:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/b2b5e122eff1f118/fda-accepts-minocycline-hydrochloride-extended-release-capsules-for-individuals-with-rosacea 2024-11-04T14:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/6518104c32ba7958/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-nation-world 2024-11-04T13:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/ff82398d7e1be3c6/cvrx-earns-medicare-win-for-barostim-procedure-massdevice 2024-11-04T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/e2749d0d5cb7d457/journey-medical-fda-approves-emrosi-for-treatment-of-inflammatory-lesions-of-rosacea 2024-11-04T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/ac8041f338dcb3a6/krystal-biotech-inc-sec-10-q-report-tradingview 2024-11-04T13:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/d23eb2d6a9606034/regorafenib-shows-survival-benefit-in-late-stage-gastric-cancer-integrate-iia-trial 2024-11-04T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/62281409066d1419/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/0b672ad6aeaec0a2/essa-pharma-downgraded-by-oppenheimer-piper-sandler-after-drug-setback-in-trials 2024-11-04T13:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/6d8e41f2d16347c4/spectral-medical-provides-october-tigris-trial-update-financial-post 2024-11-04T13:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/69d1d3b0d23e9d2a/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/7ce1086c4fcdc741/mhra-approves-cstone-pharmaceuticals-sugemalimab-to-treat-lung-cancer-in-adults 2024-11-04T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/79026703092d9438/leo-pharma-shares-final-long-term-results-for-atopic-dermatitis-drug-adbry-pmlive 2024-11-04T13:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/8fe7f988761eb511/patients-achieve-insulin-freedom-with-tegoprubart-immunotherapy 2024-11-04T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/fd458e4a956676fd/key-trials-on-parp-inhibitor-combinations-in-metastatic-prostate-cancer-urology-times 2024-11-04T13:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/ba32ac40251f705d/phase-3-data-shows-long-term-efficacy-safety-of-stapokibart-for-atopic-dermatitis 2024-11-04T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/982509a45620f7b4/cervomed-announces-key-takeaways-from-oral-presentations-at-globenewswire 2024-11-04T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/9489c130d89043f6/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T13:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/fc9e05cdd18a640c/neurobo-pharmaceuticals-completes-last-patient-last-visit-in-its-phase-2a-clinical-trial 2024-11-04T13:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/7a51149386c2b40a/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T13:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/c58ca47bd09b3780/teva-s-tev-749-yields-positive-results-in-phase-3-schizophrenia-trial 2024-11-04T12:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/56ee850ae8483390/disc-medicine-announces-successful-end-of-phase-2-meeting-globenewswire 2024-11-04T12:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/b1c909b1d56443ea/angitia-biopharmaceuticals-announces-dosing-of-first-globenewswire 2024-11-04T12:47:17+00:00 weekly 0.7 https://trial.medpath.com/news/c19912015f52e8eb/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/00c7f1d6edd5336b/record-monthly-enrollment-achieved-in-seastar-medical-s-pivotal-adult-aki-trial-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/d1a245751350c0c7/ideaya-biosciences-inc-reports-third-quarter-2024-financial-results-and-provides 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/ea5787058de8f54b/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/a11133211cb19227/journey-medical-announces-u-s-fda-approval-of-emrositm-minocycline-hydrochloride 2024-11-04T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/8d8b306a318b5416/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T12:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/39e506f94f956010/biontech-announces-third-quarter-2024-financial-results-and-corporate-update 2024-11-04T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/892fde30fa631ed4/tonix-pharmaceuticals-announces-research-agreement-with-kenya-medical-morningstar 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/4ac2f3bda967a91e/cytosorbents-submits-health-canada-medical-device-license-application-for-drugsorb 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/8995d6950bc6793b/philips-enrolls-first-patient-in-u-s-clinical-trial-to-study-highly-innovative-single-device 2024-11-04T12:18:38+00:00 weekly 0.7 https://trial.medpath.com/news/ffcc9894690477ae/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia 2024-11-04T12:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/575d7a7679c075d8/dri-healthcare-trust-announces-acquisition-of-a-synthetic-royalty-interest-in-the-markets-data 2024-11-04T12:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/83a0fb4cf84635d1/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/26210f979043a8d3/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/4148979ac95a3ac7/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-11-04T12:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/941751518d748345/atossa-therapeutics-reports-positive-karisma-endoxifen-trial-results-globenewswire 2024-11-04T11:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/0743364ef499f8d5/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T11:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/e99edc3f0a99e18a/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T11:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/ddf19acb77c23879/formosa-pharmaceuticals-announces-successful-top-line-results-from-cpn-303-a-phase 2024-11-04T11:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/ddc9ec26572e1094/novo-nordisk-reports-positive-data-from-part-one-of-semaglutide-trial-for-mash 2024-11-04T10:40:58+00:00 weekly 0.7 https://trial.medpath.com/news/0f74b6d6a940888e/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant 2024-11-04T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/56d2de77ba2cab66/shanghai-fosun-pharma-announces-drug-registration-acceptance-tipranks-com 2024-11-04T10:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/726da84ef07f1c95/korean-dementia-association-leqembi-s-side-effects-are-not-significant-komedidaskeom 2024-11-04T09:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/06f67bc71dd3322c/grand-pharmaceutical-s-breakthrough-in-ophthalmic-drug-trial-tipranks-com 2024-11-04T09:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/8f9573a21820f024/shandong-xinhua-pharmaceutical-gains-approval-for-pentazocine-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/796ce235002e56fd/shandong-xinhua-pharmaceutical-gains-key-drug-approval-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/29e55cf5625e1207/jongkundang-receives-fda-approval-for-phase-1-clinical-trial-of-new-hyperlipidemia-treatment 2024-11-04T09:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/058b5bda4689a162/pharmacists-take-leading-role-in-combating-medical-misinformation-through-evidence-based-strategies 2024-11-04T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2f1a227239655527/multiscale-mechanistic-model-of-rheumatoid-arthritis-to-enable-decision-making-in-late 2024-11-04T08:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/9a1f72498b460e51/verastem-oncology-submits-nda-to-us-fda-for-avutometinib-plus-defactinib-to-treat-pharmabiz 2024-11-04T08:29:22+00:00 weekly 0.7 https://trial.medpath.com/news/d9eca900dd412299/novo-nordisk-will-file-semaglutide-for-mash-next-year-pharmaphorum 2024-11-04T07:36:24+00:00 weekly 0.7 https://trial.medpath.com/news/c32c2b48cf5cd54f/medincell-s-partner-teva-unveils-new-phase-3-positive-results-for-olanzapine-lai-and 2024-11-04T07:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/673ade6ebc1a19ef/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/4826c3039e2c6df0/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:18:01+00:00 weekly 0.7 https://trial.medpath.com/news/54ea5b4fa365b14a/verona-pharma-reports-third-quarter-2024-financial-results-globenewswire 2024-11-04T07:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/a4df0eed82d1e4d3/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T07:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/7532b08bd0668e99/qiagen-receives-fda-clearance-of-qiastat-dx-globenewswire 2024-11-04T06:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/57b7542d6cfb4c01/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/88f55685fb9bcfa2/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/cdb8f28bcc4140b6/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/d419486c894577b3/prokarium-secures-two-us-patents-for-novel-cancer-immunotherapy-platform 2024-11-04T06:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/e8ca99418b5ecd7f/pioneering-gene-therapies-coming-from-zayed-centre-breakthroughs-the-national 2024-11-04T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/2758e10e435c5b52/experts-call-for-paradigm-shift-in-cancer-drug-dosing-moving-beyond-maximum-tolerated-dose 2024-11-04T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3998a3eca2c604e2/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and 2024-11-04T05:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/10dbffa45871178e/nanoviricides-to-provide-corporate-update-at-the-spartan-capital-investors-conference 2024-11-04T05:32:11+00:00 weekly 0.7 https://trial.medpath.com/news/26924fcad66c356e/actinogen-medical-advances-in-neurological-drug-development-markets-insider 2024-11-04T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/3d31778c49a0ee6a/fda-action-alert-journey-merus-ptc-and-autolus-biospace 2024-11-04T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/767d152b765755d0/7-alzheimer-s-and-parkinson-s-programs-discarded-in-2024-biospace 2024-11-04T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/34b71a92c941c91e/cipla-share-price-rises-11-in-three-sessions-as-brokerages-positive-on-us-fda-clearance 2024-11-04T04:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/67784a478067bcf6/successful-treatment-of-pediatric-generalized-pustular-psoriasis-gpp-dove-medical-press 2024-11-04T04:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/faebe3d67ebaf97c/court-blocks-sun-pharma-s-alopecia-drug-launch-following-incyte-patent-dispute 2024-11-04T04:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/2f9fabe5799cee6f/endevica-bio-launches-abisati-to-advance-novel-obesity-drug-710go-into-clinical-trials 2024-11-04T04:12:33+00:00 weekly 0.7 https://trial.medpath.com/news/0ca492f49e0fb073/iisc-gets-rs-52-47-crore-under-ayurswasthya-yojna-for-coe-in-ayurveda-for-diabetes-and 2024-11-04T02:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/0b90208e8b5ef2a3/first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-nature 2024-11-04T01:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/aff33446b6bca045/a-round-up-of-alzheimer-s-drug-trials-news-from-ctad-2024-being-patient 2024-11-04T01:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/8c3fd421cace07e9/fda-approves-emrosi-minocycline-hydrochloride-for-the-treatment-of-rosacea 2024-11-04T00:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/05b9c72e39584049/journey-medical-corporation-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/45c2c50f75a14476/hanall-biopharma-reports-q3-2024-financial-results-and 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7772d0eb83dafab0/a-digital-health-behavior-intervention-to-prevent-childhood-obesity-jama-network 2024-11-03T22:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/80c55bbefd8666e1/kazia-therapeutics-corporate-presentation-november-2024-marketscreener 2024-11-03T21:44:33+00:00 weekly 0.7 https://trial.medpath.com/news/a83f5892815829a1/unified-clinical-platforms-drive-efficiency-in-drug-development-through-strategic-it-models 2024-11-03T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/debc1118c6695a72/new-select-trial-analysis-with-semaglutide-2-4-mg-showed-a-significant-reduction-morningstar 2024-11-03T20:46:31+00:00 weekly 0.7 https://trial.medpath.com/news/ff71f1d47b9ba3cc/alzheimer-s-progression-may-be-slowed-by-targeted-magnetic-pulses-study-suggests 2024-11-03T20:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/b7d7d1d3bd36c331/graphene-chip-implant-in-uk-trial-could-transform-brain-tumour-surgery-the-guardian 2024-11-03T20:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/8dcb3bd8ec9e931b/adjunctive-antipsychotic-helps-ease-symptoms-of-depression-medpage-today 2024-11-03T20:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/3f2ad79e9072ce19/intas-pharmaceutical-gets-cdsco-panels-nod-to-conduct-phase-iii-clinical-trial-of-ruxolitinib-cream 2024-11-03T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/72d87c5a54a024d7/leukocytes-telomere-length-as-a-biomarker-of-adverse-drug-reactions-induced-by-nature 2024-11-03T20:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/7454123c45ef6af5/sanofi-healthcare-gets-cdsco-panel-nod-to-study-asthma-drug-sar443765 2024-11-03T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/01a80ed2936b9bd2/contributor-the-era-of-disease-modifying-alzheimer-disease-treatments 2024-11-03T19:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/6406970b1598f148/rheumatology-month-in-review-october-2024-hcplive 2024-11-03T19:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/6e430705116b3aaa/marking-a-new-era-in-patient-care-with-advancements-in-disease-modifying-alzheimer-treatments 2024-11-03T19:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/47c6716540d74be3/nda-filed-for-avutometinib-plus-defactinib-for-low-grade-serous-ovarian-cancer 2024-11-03T18:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/97a5556eef9e5d6d/cinfina-pharma-presents-positive-phase-1-study-results-in-poster-session-for-cin-109-and 2024-11-03T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/9edd4f60d6a83d94/flasco-fall-session-advancements-in-mrd-monitoring-using-ctdna-in-lung-cancer 2024-11-03T17:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/272d1ee06e8750f5/twice-yearly-lenacapavir-may-change-the-world-if-we-make-it-work-contagion-live 2024-11-03T16:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/215caa15d700a98c/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-03T15:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/9e65ac82821fa3b0/induction-chemotherapy-combination-boosts-pfs-os-in-cervical-cancer 2024-11-03T15:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/1ecf7e4a658a204a/caroline-diorio-md-frcpc-faap-on-noninflammatory-neurotoxicity-events-in-patients 2024-11-03T14:20:41+00:00 weekly 0.7 https://trial.medpath.com/news/4d29a78b671ab222/implications-of-findings-on-patient-reported-outcomes-for-roflumilast-foam-with-melinda 2024-11-03T14:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/0c346a578172c22d/new-psychiatric-technique-asks-schizophrenics-to-engage-in-dialogue-with-the-voices-futurism 2024-11-03T13:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/46690e1313a84730/why-sun-pharma-may-be-in-focus-on-monday-cnbc-tv18 2024-11-03T13:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/a1c88544dc0b3e25/comparison-of-bilicocoon-phototherapy-with-overhead-phototherapy-in-hyperbilirubinemic 2024-11-03T13:19:19+00:00 weekly 0.7 https://trial.medpath.com/news/590d53fe622a9742/role-of-tumor-specific-and-whole-body-imaging-biomarkers-for-prediction-of-recurrence-in 2024-11-03T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/e7ef6477e0ea247a/shuttle-pharmaceuticals-holds-public-offering-to-advance-clinical-trials-defense-world 2024-11-03T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/2bb450a38059ec99/the-targeted-pulse-uncover-the-latest-from-wclc-and-experts-insights-into-latest 2024-11-03T12:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/fbbef6a18628f4d3/earnings-call-takeda-reports-robust-h1-growth-revises-full-year-guidance-investing-com 2024-11-03T11:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/aeab62e710176f70/shr-a1921-demonstrates-early-efficacy-in-platinum-resistant-ovarian-cancer-onclive 2024-11-03T11:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/cbda3f34a02fe3b1/the-r-o-a-d-to-precision-medicine-nature 2024-11-03T09:40:29+00:00 weekly 0.7 https://trial.medpath.com/news/168eddbd8ffcf01b/clinical-trial-alpha-1-antitrypsin-deficiency-aatd-nct06622668-crispr-medicine 2024-11-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/194303c86645a4f1/16-hospitals-test-potentially-life-saving-device-designed-for-indian-stroke-patients 2024-11-03T09:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/a6d71b6c04b345d0/debra-miller-los-angeles-times 2024-11-03T09:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/f6e65467e485d99a/novel-anti-mdm2-protac-shows-promise-for-p53-mutated-cancer-treatment 2024-11-03T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b014eeb95e8988c/the-scientist-who-tested-his-revolutionary-medicine-on-his-own-brain-cancer-the-guardian 2024-11-03T07:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/29d9dfc0b0fb14d1/real-world-evidence-for-pembrolizumab-in-non-small-cell-lung-cancer-a-nationwide-cohort-study 2024-11-03T07:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/2b4754fa1fbdff84/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-03T05:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/8c006623cf417a9f/the-european-medicines-agency-approves-the-moderna-vaccine 2024-11-03T03:43:43+00:00 weekly 0.7 https://trial.medpath.com/news/3a9b7504ea2a6c7d/innocare-pharma-sehk-9969-achieves-key-milestone-with-icp-488-phase-ii-success-in 2024-11-03T00:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/cfb23c9544fd2b03/mtnb-matinas-biopharma-holdings-inc-latest-stock-news-market-updates 2024-11-03T00:29:30+00:00 weekly 0.7 https://trial.medpath.com/news/e2bfef76625a26cb/driver-mutations-associated-with-signatures-of-platinum-sensitivity-in-germ-cell-tumors 2024-11-03T00:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/016aebcc45e627d7/semaglutide-shows-promise-for-osteoarthritis-pain-relief-the-pinnacle-gazette 2024-11-02T23:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/667f5af3b53548c7/hospital-tries-car-t-therapy-for-lung-cancer-shine-news-shanghai-daily 2024-11-02T23:28:57+00:00 weekly 0.7 https://trial.medpath.com/news/70eadf7709c12fd8/efficacy-of-xanomeline-and-trospium-chloride-in-schizophrenia-pooled-results-from-three-5 2024-11-02T23:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/b8c1beb571504dec/merus-annonce-ses-resultats-financiers-pour-le-troisieme-globenewswire 2024-11-02T22:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/73dcd49650e922bb/clinical-trial-solid-tumors-nct06598371-crispr-medicine-news 2024-11-02T21:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/8e3cc440148745e2/clinical-trial-hereditary-angioedema-hae-nct06634420-crispr-medicine-news 2024-11-02T21:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/7583eed57da162ea/uk-s-nice-says-alzheimer-s-disease-drug-kisunla-is-not-cost-effective-forbes 2024-11-02T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/8345eff1984ce02a/bringing-precision-medicine-to-psychiatry-circular-rnas-as-a-window-into-the-brain-nature 2024-11-02T19:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/fedc1261c9292cba/hoping-for-a-weight-loss-pill-it-could-get-closer-to-reality-next-week-morningstar 2024-11-02T18:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/9e504b9274e73d65/gastroenterology-month-in-review-october-2024-hcplive 2024-11-02T18:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/f35ed7f96b48ae29/remission-rate-toxicity-and-pharmacokinetics-of-venetoclax-based-induction-regimens-in-nature 2024-11-02T17:45:04+00:00 weekly 0.7 https://trial.medpath.com/news/28ac280486b20739/enhanced-dosing-of-donanemab-lowers-aria-risk-anti-tau-agent-e2814-shows 2024-11-02T17:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/3e48d3864c6291b1/asco-seeks-to-expand-pharmacist-membership-and-engagement-in-oncology-standards-development 2024-11-02T16:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/4c379d58b5e9c8a7/this-week-in-ophthalmology-week-of-october-26-2024 2024-11-02T16:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/12838829ad9900ba/semaglutide-so-effective-at-treating-arthritis-that-patients-were-more-or-less-were-futurism 2024-11-02T16:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/0291404f85542365/cancer-policy-monitor-november-12-2024-aacr 2024-11-02T16:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/3dad2caafef70e1e/madrigal-89bio-jump-after-novo-s-semaglutide-shows-promise-in-mash-yahoo-finance 2024-11-02T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/ac5fb34365407905/guanxinning-for-residual-inflammation-of-stable-coronary-artery-diseas-dove-medical-press 2024-11-02T15:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/1f0103bafbcd391a/bath-hospital-needs-volunteers-for-stroke-drug-study-bbc 2024-11-02T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/62294a3b27b7e6dc/fda-panel-votes-against-sotagliflozin-for-glucose-control-in-type-1-diabetes-ckd-healio 2024-11-02T14:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/61bc92d6bfd4fab8/bravo-trial-highlights-improved-detection-reduces-bladder-cancer-recurrence-from-urotoday 2024-11-02T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/52d57f2109b6a271/omega-3-supplements-show-benefit-in-apoe4-carriers-medpage-today 2024-11-02T14:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/1b4b22025346e936/is-it-really-cancer-more-concerns-about-accelerated-approval-metformin-and-cancer 2024-11-02T14:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/0c3cd977e1ed2e89/compass-pathways-cuts-30-of-workforce-on-phase-3-trial-delays-yahoo-finance 2024-11-02T13:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/31310c0c27adc480/pharma-stock-roundup-mrk-pfe-abbv-nvs-lly-s-q3-earnings-in-focus 2024-11-02T13:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/070bf4522339b1e4/benefit-of-systemic-therapy-in-mindact-patients-with-small-er-positive-her2-negative 2024-11-02T13:25:31+00:00 weekly 0.7 https://trial.medpath.com/news/4c0a01f7884d7023/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-globenewswire 2024-11-02T13:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/bdec1120974012a8/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-medicalnewstoday 2024-11-02T13:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/9431f3ec189019e4/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-02T13:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/81f5f53ac9f96d79/nyu-langone-health-in-the-news-friday-november-1-2024 2024-11-02T12:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/da1688261a5fe5ce/oikn-partners-with-us-companies-to-develop-command-center-concept-antara-news 2024-11-02T12:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/f2b4c6aa7ff4abe7/biosimilars-month-in-review-october-2024-hcplive 2024-11-02T12:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/75c78b32b9b04641/fda-panel-rejects-sglt1-2-inhibitor-for-type-1-diabetes-medpage-today 2024-11-02T11:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/8d6abe84caff3a5b/alzheimer-s-researchers-say-brain-stimulation-device-may-slow-symptoms-nbc-news 2024-11-02T11:34:45+00:00 weekly 0.7 https://trial.medpath.com/news/a42337de5ab137a9/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-02T11:34:21+00:00 weekly 0.7 https://trial.medpath.com/news/1f125ae6ae0f5e4b/vyn201-for-vitiligo-phase-1b-study-confirms-safety-dermatology-times 2024-11-02T11:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/cccef0a54bb5623d/new-alzheimer-s-resource-center-opening-in-oak-cliff-cbs-news 2024-11-02T11:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/f8e3677c8b4fccae/phase-ii-trial-evaluating-the-long-term-efficacy-and-peripheral-sensory-neuropathy-of-nature 2024-11-02T11:02:57+00:00 weekly 0.7 https://trial.medpath.com/news/7920201cb9610e15/alx-oncology-announces-results-from-phase-1b-2-trial-of-globenewswire 2024-11-02T09:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/e4751a56abba109a/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and 2024-11-02T09:30:38+00:00 weekly 0.7 https://trial.medpath.com/news/be9d7f6e27c1fa09/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc-onclive 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/f6ef70a6a7dfda44/indirect-comparison-shows-superiority-of-cilta-cel-vs-soc-regimens-in-lenalidomide 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/c437a2864c6e9d16/fda-approval-sought-for-avutometinib-plus-defactinib-in-recurrent-kras-low-grade-onclive 2024-11-02T09:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/9b70f48f347f2c05/cms-grants-transitional-pass-through-payment-for-medtronic-symplicity-spyraltm-renal 2024-11-02T09:24:41+00:00 weekly 0.7 https://trial.medpath.com/news/1bf9139209c55207/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-02T08:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/353ee2a6b66f317a/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/2f8dfa05dd70899f/oncoinvent-announces-publication-of-18-month-safety-and-efficacy-data-from-the-phase-1 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/ef3944106cd7955f/disc-medicine-to-host-conference-call-on-end-of-phase-2-fda-globenewswire 2024-11-02T08:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/2db7235287cc8123/infliximab-monotherapy-effective-as-combo-therapy-for-treating-inflammatory-bowel-disease 2024-11-02T07:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/5a8d0e1982f20007/verastem-oncology-submits-nda-for-ovarian-cancer-treatment-pharmaceutical-technology 2024-11-02T07:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/6edbfd9972d7e185/cgtlive-r-s-weekly-rewind-november-1-2024 2024-11-02T07:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/e2dd3266fdbad143/less-frequent-elfabrio-dosing-for-fabry-disease-appears-to-be-safe-effective 2024-11-02T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/a6eb32e12d618f38/blue-earth-therapeutics-reports-promising-phase-1-data-for-investigational-therapies 2024-11-02T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/fff29731d3e5a670/teva-presents-phase-3-solaris-trial-results-markets-insider 2024-11-02T06:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/d9d3f99930ca86dc/predicting-deterioration-in-dengue-using-a-low-cost-wearable-for-continuous-clinical-monitoring 2024-11-02T05:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/cde0ed34012a014a/bullous-pemphigoid-executive-insights-bullous-pemphigoid-executive-insights-us-eu5 2024-11-02T05:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/71bfdcd0c6e14b38/ai-algorithm-shows-promise-in-early-detection-of-rare-blood-disorder-pnh 2024-11-02T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/838e5a8ee4c3c9b8/fda-grants-orphan-drug-designation-to-cap-002-to-treat-patients-with-developmental-and 2024-11-02T04:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/d557e5ed7fc70d9e/novo-nordisk-glp-1-drug-meets-goals-of-mash-trial-setting-stage-for-fda-ema-filings 2024-11-02T04:31:49+00:00 weekly 0.7 https://trial.medpath.com/news/2da81121bfa5617c/fda-approves-new-drug-for-schizophrenia-promises-few-side-effects-straight-arrow-news 2024-11-02T04:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/694f86db382d5b01/managing-amivantamab-s-complex-safety-profile-new-strategies-for-egfr-positive-nsclc-treatment 2024-11-02T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/64199bfa40e55028/rolling-nda-completed-for-avutometinib-combo-in-ovarian-cancer-subtype 2024-11-02T04:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/a4524f1f3492c0b5/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-aol-com 2024-11-02T03:32:08+00:00 weekly 0.7 https://trial.medpath.com/news/ed7e41f1d56e9313/fda-advisory-committee-votes-down-sotagliflozin-in-type-1-diabetes-and-ckd 2024-11-02T03:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/4e86b92afb9b6e3a/rifaximin-reduced-overt-hepatic-encephalopathy-recurrence-over-lactulose 2024-11-02T03:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/39bd164b6b3d12b4/novel-immunotherapy-combo-shows-promise-in-melanoma-eurekalert 2024-11-02T02:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/f8a8e2f9c6121cf3/dkn-01-with-tislelizumab-and-chemotherapy-in-advanced-gastric-or-gastroesophageal 2024-11-02T02:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/2edca57e915853b3/revisit-every-onclive-on-air-episode-from-october-2024 2024-11-02T02:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/16d7f00fffad8caa/inavolisib-regimen-continues-to-improve-survival-in-pik3ca-mutated-breast-cancer 2024-11-02T02:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/b6a5831aa1cf579e/study-reveals-critical-care-gaps-and-economic-burden-for-metastatic-bone-disease-patients 2024-11-02T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d241be8a33d70dfe/lexicon-stock-tumbles-after-fda-adcom-votes-against-zynquista-again 2024-11-02T01:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/d20f5d4d209dfdf0/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough-hearing 2024-11-02T00:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/692097599b7461da/atezolizumab-matched-targeted-therapy-improves-os-in-anaplastic-thyroid-cancer 2024-11-02T00:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/7175dc6f4b5a05f8/wegovy-demonstrates-superiority-over-placebo-in-patients-with-metabolic-dysfunction 2024-11-01T23:53:15+00:00 weekly 0.7 https://trial.medpath.com/news/1dbb4b335819c578/recor-medical-announces-cms-grant-of-transitional-pass-through-tpt-payment-tradingview 2024-11-01T23:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/fcbf28ded5c5df80/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-11-01T23:28:12+00:00 weekly 0.7 https://trial.medpath.com/news/887206a54ecfbeb1/study-reveals-encouraging-results-in-her2-breast-cancer-with-brain-mets 2024-11-01T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/7308ca4fee03218b/court-denies-jazz-s-challenge-of-avadel-s-orphan-drug-lumryz-sleep-review 2024-11-01T22:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/92b7407b3a51e7ca/breakthrough-in-cancer-treatment-implantable-microparticles-deliver-dual-therapies 2024-11-01T22:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/84322d4829bfaf30/fda-clears-irhythm-s-second-510-k-in-response-to-warning-letter-medtech-dive 2024-11-01T22:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/e9cac8220f5c0551/baili-tianheng-688506-rapid-promotion-of-innovation-pipeline-and-active-layout-of-yicai-global 2024-11-01T22:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/ee2b175ba788f18b/alx-oncology-announces-results-from-phase-1b-2-trial-of-evorpacept-in-combination-with 2024-11-01T21:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/337f0e7d92e0c858/cmn-weekly-1-november-2024-your-weekly-crispr-medicine-news 2024-11-01T21:36:55+00:00 weekly 0.7 https://trial.medpath.com/news/7765d1c06c060013/a-sickle-cell-cure-exists-but-patients-need-more-than-just-gene-therapy-pharmavoice 2024-11-01T21:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/7568a5736fa30cd9/eisai-formally-submits-bla-for-subcutaneous-autoinjector-of-lecanemab-neurologylive 2024-11-01T21:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/11b44e515a218e43/ameluz-pdt-leads-to-target-lesion-clearance-in-superficial-basal-cell-carcinoma 2024-11-01T21:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/63cc9a0f7281d54f/fda-clears-ai-tool-that-flags-signs-of-heart-disease-in-chest-ct-scans 2024-11-01T21:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/36f53e052f0309fb/novo-s-wegovy-comparable-to-madrigal-s-rezdiffra-in-phase-iii-mash-trial-analysts 2024-11-01T21:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/dec2899a265d0d20/vir-biotechnology-inc-vir-q3-2024-earnings-call-highlights-st-gurufocus 2024-11-01T21:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/6a46036bc13a9731/does-an-additional-first-line-option-alter-approach-in-egfr-mutant-nsclc 2024-11-01T20:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/9939dc2743a588b0/glaucoma-drug-shows-promise-in-targeting-tau-buildup-inside-precision-medicine 2024-11-01T20:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/4593c30707fe7772/eliminate-trial-uuti-regimen-demonstrates-initial-tolerability-efficacy-urology-times 2024-11-01T20:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/0e3e229d5ef20095/fda-panel-rejects-lexicon-s-zynquista-for-type-1-diabetes-benzinga 2024-11-01T20:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/c48ba7ad5ddbdaf0/feliqs-receives-u-s-fda-fast-track-designation-for-flq-101-a-first-in-class-small-biospace 2024-11-01T20:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/f6351f5d90efb9d2/earnings-call-compass-pathways-reports-q3-results-and-trial-updates-investing-com 2024-11-01T19:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/985e77c442067823/nvo-reports-positive-phase-iii-trial-results-for-semaglutide-in-mash-treatment 2024-11-01T19:25:17+00:00 weekly 0.7 https://trial.medpath.com/news/f8055a08678f1e1b/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-01T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/news/d4f7305727d66aa5/casdatifan-demonstrates-durable-activity-in-metastatic-clear-cell-renal-cell-carcinoma 2024-11-01T19:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/527c54f24c535ee9/fda-s-october-2024-highlights-advancing-treatments-in-oncology 2024-11-01T19:17:33+00:00 weekly 0.7 https://trial.medpath.com/news/3c2295c5f2a99883/oncology-drugs-approved-by-the-fda-in-october-2024-cure-today 2024-11-01T19:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/853c68e07cb01d02/novo-nordisk-a-s-semaglutide-2-4-mg-demonstrates-superior-globenewswire 2024-11-01T18:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/bd7ebd1239758b44/two-topical-treatments-show-similar-benefits-for-photoaging-of-the-hands-news-medical 2024-11-01T18:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4ca8e5aca20034a/stelara-may-be-effective-for-type-1-diabetes-in-adolescents 2024-11-01T18:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/07c1e8edac9850eb/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-01T18:00:25+00:00 weekly 0.7 https://trial.medpath.com/news/2ed680598d3b7667/eisai-completes-rolling-biologics-license-application-to-fda-for-subcutaneous 2024-11-01T17:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/3f1afe7a929f3d17/lexicon-loses-fda-adcomm-vote-on-insulin-adjunct-for-patients-with-type-1-diabetes 2024-11-01T17:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/264071b2c8b035fe/phase-iii-trials-show-long-term-efficacy-of-cobenfy-treating-schizophrenia 2024-11-01T17:36:59+00:00 weekly 0.7 https://trial.medpath.com/news/194b5bac107c401b/anti-tau-antibody-stumbles-in-phase-ii-alzheimer-trial-nature 2024-11-01T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/267852448badb5b2/ucb-weighs-up-alzheimer-s-drug-future-after-phase-ii-miss-and-roche-exit-scrip 2024-11-01T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/130b935c1c32b3ae/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T17:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/34f176a0635a1c00/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T17:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/360e88b45cba8e51/tizona-s-ttx-080-colorectal-cancer-trial-expands-with-new-arms 2024-11-01T17:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/7a44f429e7f87156/fda-approves-scemblix-for-newly-diagnosed-cml-patients-the-cancer-letter 2024-11-01T16:51:12+00:00 weekly 0.7 https://trial.medpath.com/news/3eebfcdb876ad19f/phase-2-trial-of-masofaniten-plus-enzalutamide-in-mcrpc-has-been-terminated 2024-11-01T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/fedc78614ac19ac1/high-grade-cesium-results-continue-in-latest-drilling-phase-nationtalk 2024-11-01T16:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/c594793b786c5274/novo-with-new-results-to-seek-approval-for-obesity-drug-in-mash-biopharma-dive 2024-11-01T16:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/a6a12dd0907db7a0/clinical-trials-red-tape-and-ethics-under-the-microscope-research-professional-news 2024-11-01T16:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/611615b37908447d/recce-pharmaceuticals-reports-solid-progress-in-clinical-trials-raises-a-12-5-million-in 2024-11-01T16:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/067df6b97da84f89/predicting-pathological-response-of-neoadjuvant-conversion-therapy-for-jhc-dove-medical-press 2024-11-01T16:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/0f7c2142b9cc9940/powering-a-new-paradigm-for-pathology-danaher 2024-11-01T16:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/f4ea0aea32915db5/a-narrative-review-focusing-on-randomized-clinical-trials-rcts-of-vitamin-d-frontiers 2024-11-01T16:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/83d2280a7bca28b5/breakthrough-t1d-expresses-disappointment-in-fda-advisory-committee 2024-11-01T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/2265947419df73f3/treatments-in-clinical-trials-for-small-cell-lung-cancer-healthline 2024-11-01T15:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/91a11407a8dfd5ca/us-court-upholds-avadel-s-narcolepsy-drug-approval-amid-exclusivity-battle 2024-11-01T15:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/acc121cca5af9a85/taking-on-acquired-resistance-in-egfr-mutant-nsclc-medpage-today 2024-11-01T15:35:14+00:00 weekly 0.7 https://trial.medpath.com/news/b5dd9c859086788c/year-in-review-non-small-cell-lung-cancer-medpage-today 2024-11-01T15:35:12+00:00 weekly 0.7 https://trial.medpath.com/news/4b9424e94ca91f11/insomnia-breakthrough-handheld-device-in-development-may-soon-zap-away-sleepless-nights 2024-11-01T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/d76825f480403183/envoy-medical-receives-fda-approval-to-initiate-pivotal-globenewswire 2024-11-01T15:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/c516c7d34ae977fe/inotuzumab-ozogamicin-with-low-intensity-chemotherapy-in-older-patients-with-cd22 2024-11-01T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/6a9d02243ccdfc95/online-yoga-classes-can-ease-lower-back-pain 2024-11-01T15:11:43+00:00 weekly 0.7 https://trial.medpath.com/news/05f4c9c2caaa7c82/earnings-call-vir-biotechnology-advances-with-sanofi-deal-hepatitis-trials-investing-com 2024-11-01T15:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/bb2a5101c433003c/chemo-should-be-tailored-to-decrease-neuropathy-in-black-patients-oncology-nursing-news 2024-11-01T15:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/6f5d51817fe14638/effectiveness-of-virtual-yoga-for-chronic-low-back-pain-a-randomized-clinical-trial 2024-11-01T15:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/afb9cfbc1795ea38/fda-roundup-agency-highlights-from-october-2024-drug-topics 2024-11-01T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/58a38ea9c4c567a9/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T14:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/2b3d379216f53eca/regeneron-battles-wall-street-uncertainty-madrigal-extends-fast-launch-of-mash-drug 2024-11-01T14:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/4c8ea6c7b56c8704/obesity-is-the-new-hypertension-the-current-landscape-of-pharmacological-weight-loss 2024-11-01T14:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/4cccac40f9f9f7c9/video-experts-consider-endpoints-for-clinical-trials-in-geographic-atrophy-healio 2024-11-01T14:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/b73f94f8b3e9ee72/uk-approves-cstone-s-sugemalimab-for-non-small-cell-lung-cancer-treatment 2024-11-01T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/1e0a384515ce3886/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-01T14:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/cd98a10ae1f6e51a/eisai-biogen-eye-2025-approval-for-leqembi-autoinjector-pharmaphorum 2024-11-01T14:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/d776f4daec7d9f4f/hansoh-pharmaceutical-group-company-limited-announces-the-nmpa-has-granted 2024-11-01T14:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/bd0afdfddf4a1f73/overcollection-of-data-adds-months-to-clinical-trials-and-reduces-roi-finds-new-phesi-analysis 2024-11-01T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/959d0b7822734223/pl-developments-receives-fda-approval-for-over-the-counter-omeprazole 2024-11-01T13:36:37+00:00 weekly 0.7 https://trial.medpath.com/news/8b9d501f2a0524a6/earnings-call-insmed-reports-strong-q3-growth-eyes-brensocatib-launch-investing-com 2024-11-01T13:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/d00838c7ef16bbae/with-new-wegovy-data-in-hand-novo-nordisk-will-file-for-approval-in-mash-stat-news 2024-11-01T13:24:12+00:00 weekly 0.7 https://trial.medpath.com/news/eac71ea47990d104/alzheimer-s-can-new-blood-tests-help-diagnose-the-disease-early-medicalnewstoday 2024-11-01T13:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/c55a7a4f105f88cd/readout-newsletter-madrigal-eli-lilly-compass-pathways-latest-stat-news 2024-11-01T13:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/47c0286ced7b6956/break-through-cancer-announces-first-patient-enrolled-in-phase-2-trial-targeting-residual 2024-11-01T12:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/7147886158049a75/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:43:03+00:00 weekly 0.7 https://trial.medpath.com/news/b5064770cda346c7/disparities-in-ibs-clinical-trial-participation-suggest-healthcare-research-inequities 2024-11-01T12:40:51+00:00 weekly 0.7 https://trial.medpath.com/news/7a361c551089ff4f/johnson-johnson-medtech-concludes-enrolment-for-omny-af-trial-pilot-phase 2024-11-01T12:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/6353b635fcb30402/sotagliflozin-setback-cautionary-fda-adcomm-vote-reflects-continued-concern-for 2024-11-01T12:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/0a2800a81d1414c2/dijon-biotech-company-inventiva-raises-348-million-to-complete-its-phase-iii-born2invest 2024-11-01T12:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/18d1a07c597fa0f8/corcept-s-relacorilant-gradient-trial-misses-primary-endpoint 2024-11-01T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ac0eeec0b2a0632/roche-weighs-whether-speedy-approval-path-is-open-for-latest-alzheimer-s-drug 2024-11-01T12:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/9ee4fc75ecd073df/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml-pmlive 2024-11-01T12:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/b96e929e031e7098/dermavant-reports-positive-long-term-results-for-vtama-cream-in-atopic-dermatitis-pmlive 2024-11-01T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/58b91baa779c7981/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/bf00db9bce468eff/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-01T12:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/7ca45cd715d8f921/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/6f076da0395f739d/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/1bf4acedb2c1ed8b/mechanisms-of-acquired-resistance-in-first-line-treatment-amivantamab-plus-lazertinib 2024-11-01T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/1f4e4d960f52dfcf/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/d52f0df7c4536f66/seltorexant-shows-promise-as-first-in-class-treatment-for-depression-with-insomnia-in-phase-iii-trial 2024-11-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75d39516f61590e9/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-in-combination-with-keytruda 2024-11-01T11:44:59+00:00 weekly 0.7 https://trial.medpath.com/news/6f4fbb74b5343569/earnings-call-galapagos-reports-solid-q3-progress-eyes-ind-studies-investing-com 2024-11-01T11:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/85dc76e6ce01761f/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T11:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/77648d6c716fa773/breakthrough-in-treatment-of-arteriovenous-malformation-shine-news-shanghai-daily 2024-11-01T11:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/bf2f890fbe1470f8/ondine-raising-ps8-5m-to-fund-us-clinical-trial-sharecast-com 2024-11-01T11:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/5fe06f7ae5665113/memo-therapeutics-ag-announces-last-patient-enrolled-in-globenewswire 2024-11-01T11:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/69bcc8ea8e80df79/aim-vaccine-co-ltd-announces-13-valent-pneumonia-conjugate-vaccine-marketscreener 2024-11-01T11:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/5e537e1eb785e616/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-morningstar 2024-11-01T11:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/a161ce3d890bb91d/diadem-unveils-novel-findings-on-early-alzheimer-s-disease-detection-using-p53-specific-antibody-at-ctad-2024 2024-11-01T11:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/2ce392329d4acd6d/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of 2024-11-01T11:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/c4e5c2023cd37f08/clinical-trials-revised-implementing-regulations-of-the-human-research-act-swissmedic 2024-11-01T10:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/c73ea6f7a378e5dd/lexicon-s-type-1-diabetes-drug-voted-down-by-fda-adcomm-pharmaphorum 2024-11-01T10:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/2e3c4e0b9920e8e7/no-evidence-adults-with-autism-are-more-vulnerable-to-criminals-study-finds 2024-11-01T10:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/2553bb5541760da1/ozempic-wegovy-could-help-ease-knee-arthritis-pain 2024-11-01T10:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/619d35bff44eb06d/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T10:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/c539c5e6853a24e0/hansoh-pharma-s-breakthrough-in-cancer-drug-development-tipranks-com 2024-11-01T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/8bbaa1a87c2b9c74/8th-summit-advances-antigen-specific-immune-tolerance-therapies-for-autoimmune-diseases 2024-11-01T09:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/562dbeb62dcf8368/fda-adcomm-votes-against-lexicon-type-1-diabetes-and-ckd-drug-endpoints-news 2024-11-01T09:11:03+00:00 weekly 0.7 https://trial.medpath.com/news/aae2e07cc3bbdfa3/reductions-in-substance-use-as-outcome-targets-for-treatment-development 2024-11-01T08:51:18+00:00 weekly 0.7 https://trial.medpath.com/news/525dc1f94df84829/eisai-biogen-eye-2025-approval-for-subcutaneous-leqembi-pharmaphorum 2024-11-01T08:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/3094203eea33ed28/new-trials-for-potential-flu-and-norovirus-vaccines-dartmouth-today-co-uk 2024-11-01T08:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/47428e1143cbc2cf/blue-therapeutics-gets-financing-to-push-radiotherapies-european-biotechnology 2024-11-01T07:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/a2f3e9884751c4f0/recruiting-and-retaining-healthcare-workers-in-scotland-to-a-longitudinal-covid-19-study 2024-11-01T07:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/4042d8eac2590d89/incorporating-external-controls-in-the-design-of-randomized-clinical-trials-a-case-study-in-solid-tumors 2024-11-01T07:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/700b446c97b80526/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-biospace 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/a2b78c365e6221aa/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/e17d1a983c09dbe3/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/aa5ed30ffaf80c52/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/c64ea3c3e3236fa8/regeneron-reports-third-quarter-2024-financial-and-operating-results-biospace 2024-11-01T07:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/e8366c100ca0df89/h-lundbeck-a-s-announces-positive-results-from-phase-iii-pivotal-trial-of-vyepti 2024-11-01T07:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/22e89b3178ddff22/opdivo-and-yervoy-may-improve-survival-for-resected-stage-3-4-melanoma-cure-today 2024-11-01T07:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/cfafdaccd923b7cd/alnylam-pharmaceuticals-inc-alny-q3-2024-earnings-highlights 2024-11-01T07:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/12c1c845528fffb5/agios-pharmaceuticals-inc-agio-q3-2024-earnings-call-highlights-strong-cash-position-and 2024-11-01T07:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/4df4ac99d32f2ba9/rosella-trial-of-relacorilant-targets-stress-response-to-overcome-chemoresistance-in 2024-11-01T06:59:03+00:00 weekly 0.7 https://trial.medpath.com/news/ef4360f9e7f9309f/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-to-ethics-and-regulation 2024-11-01T06:03:32+00:00 weekly 0.7 https://trial.medpath.com/news/adee961ce80b6fab/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-acn-newswire 2024-11-01T05:56:35+00:00 weekly 0.7 https://trial.medpath.com/news/4c6a424e7541af0d/dr-kotecha-on-the-fda-approval-of-optune-lua-in-metastatic-nsclc-onclive 2024-11-01T05:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/e5105935f26b97dd/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T05:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/33e0c4d55cb9c785/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimer-s-disease-in-phase-2a 2024-11-01T05:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/b20afc5ef2dc1aa1/critical-drug-shortages-persist-in-us-adhd-medications-chemotherapy-drugs-and-insulin-among-most-affected 2024-11-01T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/25e9affa7f54be4b/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-biospace 2024-11-01T04:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/88b63efbb71ac8c4/study-cholinesterase-inhibitors-show-promise-for-lewy-body-dementia-being-patient 2024-11-01T04:38:43+00:00 weekly 0.7 https://trial.medpath.com/news/88872e2e9707ea12/handok-s-rare-blood-disorder-treatment-empaveli-wins-insurance-coverage-kbr 2024-11-01T04:26:27+00:00 weekly 0.7 https://trial.medpath.com/news/049ef67fa767a9f9/dimerix-collaborates-with-neptune-for-trial-recruitment-markets-insider 2024-11-01T02:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/1744abf4829a0e3c/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T02:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/55cfab60765a097d/first-fda-approved-treatment-to-delay-type-1-diabetes-ucsf-diabetes-center-57b993 2024-11-01T02:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/f9557ec0bb92cde6/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T02:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/584d6a09c94a3d17/fda-clears-exactech-porous-3d-tibial-implant-for-knee-replacement-massdevice 2024-11-01T02:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/3e8a01cff488bd36/glaucoma-drug-may-pave-unexpected-road-to-a-dementia-cure-study-finds 2024-11-01T02:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/6a0b8aa2b3afa03c/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-01T01:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/363c762ff24d7ead/new-fda-approved-treatment-for-hyperhidrosis-slucare-health-watch-826020 2024-11-01T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/065c519a2b342c4d/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined 2024-11-01T01:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/eb9d9385790eec8b/prolong-pharmaceuticals-gains-us-fda-fast-track-designation-for-novel-stroke-therapy 2024-11-01T00:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/0b94077ff0a80bc0/amgen-whets-investors-appetites-for-maritide-obesity-data-by-end-of-year-biospace 2024-11-01T00:38:59+00:00 weekly 0.7 https://trial.medpath.com/news/dfaec3d9f5a44776/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/9264f82c924be561/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/0e59da29709ac00c/elexacaftor-tezacaftor-ivacaftor-shows-promise-for-cystic-fibrosis-patients-without-f508del-cftr-variant 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff43add90837d2c7/tct-2024-one-year-data-from-sirona-trial-show-similar-results-for 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dfd7f4830d298e26/immunochemotherapy-shows-promise-for-borderline-resectable-esophageal-cancer-conversion-surgery 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1f24cff391db9d62/fda-accepts-elevar-s-resubmitted-rivoceranib-and-camrelizumab 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c349a1c7f6fd844/study-evaluates-recurrence-of-disease-activity-after-ocrelizumab-discontinuation-in-ms-patients 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cec09f61022fcea6/primary-day-28-analysis-of-a-phase-2-3-open-label-study 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7dc6cf0938648fcd/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:51:49+00:00 weekly 0.7 https://trial.medpath.com/news/a497772d3ca0da3e/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/687470209e65b680/lexicon-pharmaceuticals-gets-negative-fda-panel-vote-for-zynquista-update 2024-10-31T23:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/5f945189433993fe/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate 2024-10-31T23:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/109bb10ac3e6493a/lexicon-announces-outcome-of-fda-advisory-committee-for-globenewswire 2024-10-31T22:59:03+00:00 weekly 0.7 https://trial.medpath.com/news/5773d698a59ba85f/scs-aua-2024-indications-and-outcomes-for-radiation-therapy-in-renal-masses 2024-10-31T22:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/8878eaaefca411c7/multicenter-group-compares-real-world-mesothelioma-outcomes-to-clinical-study 2024-10-31T22:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/1ecc39b5a7e3b867/edwards-medtronic-and-inari-share-trial-data-at-tct-conference-medtech-dive 2024-10-31T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/171ca9fca54cd501/tyra-300-shows-encouraging-safety-efficacy-in-fgfr3-metastatic-urothelial-carcinoma 2024-10-31T22:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/7b6380869f0c2583/sugemalimab-plus-chemotherapy-earns-uk-approval-in-first-line-metastatic-nsclc 2024-10-31T21:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/b2a44d4fefb9da34/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T21:47:45+00:00 weekly 0.7 https://trial.medpath.com/news/843d3d8d342f59b6/the-changing-landscape-of-ph-positive-all-targeted-oncology 2024-10-31T21:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/392f466104c5635a/roche-s-antibody-against-alzheimer-s-looks-the-best-yet-barron-s 2024-10-31T21:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/22c62e8eeff33e7f/clindamycin-and-bacterial-load-reduction-as-prophylaxis-for-surgical-site-infection-racgp 2024-10-31T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/f812053bfa20b8c5/dermatology-times-october-2024-recap 2024-10-31T21:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/a7ec258040cccb73/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquista-sotagliflozin-as-an-adjunct-to-insulin-therapy-for-glycemic-control-in-adults-with-type-1-diabetes-and-chronic-kidney-disease 2024-10-31T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/0e5d899b23d061ce/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T21:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/e1bb1595a940ef72/dr-pabon-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/ee46e85a6424e4f2/dr-foss-on-the-fda-approval-of-denileukin-diftitox-for-ctcl-onclive 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/fe9997f71ec60c07/abeona-therapeutics-resubmits-bla-to-fda-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-10-31T20:48:42+00:00 weekly 0.7 https://trial.medpath.com/news/d47e7002016ce129/jefferies-raises-kymera-therapeutics-target-to-59-on-immunology-and-inflammation-focus 2024-10-31T20:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/5ad51304cbe2ae5b/inmune-bio-inc-sec-10-q-report-tradingview 2024-10-31T20:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/2c1e3e31698a7c97/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/475226fa0cf55b52/novartis-continues-to-fill-its-malaria-pipeline-with-a-long-half-life-iv-compound-for-severe-malaria 2024-10-31T20:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/01305667e6258d12/inmune-bio-inc-announces-third-quarter-2024-results-and-provides-business-update 2024-10-31T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/30e67ca7a676dd02/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/aa012445b5f57063/inavolisib-regimen-approval-opens-the-door-for-triplet-therapies-in-hr-her2-breast-cancer 2024-10-31T20:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/d611e46142551775/astrazeneca-s-wainzua-gains-another-approval-in-england-and-wales-pharmtech 2024-10-31T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/250726390da2e881/iovance-biotherapeutics-to-host-third-quarter-and-globenewswire 2024-10-31T20:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/e6eedb58486a1c01/lecanemab-data-presented-at-ctad-on-early-initiation-and-long-term-treatment-suggest 2024-10-31T19:50:58+00:00 weekly 0.7 https://trial.medpath.com/news/3d37cfa03f9c5f86/st-luke-s-surgeon-honored-for-research-work-lvb-lehigh-valley-business 2024-10-31T19:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/6421b0533f05bd66/roche-announces-phase-iii-inavo120-results-were-published-markets-insider 2024-10-31T19:45:26+00:00 weekly 0.7 https://trial.medpath.com/news/c864320d343eb405/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T19:39:17+00:00 weekly 0.7 https://trial.medpath.com/news/9f7b4ddf7e6b7308/amgen-earns-higher-revenues-in-q3-2024-puts-rare-diseases-in-the-spotlight 2024-10-31T19:35:29+00:00 weekly 0.7 https://trial.medpath.com/news/173997ee8045569c/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/21171e380a0a7000/a-promising-schizophrenia-drug-showed-mixed-results-what-does-that-mean-for-patients 2024-10-31T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/5c848a50f246b5f3/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/50b02637f496bfdf/starget-pharma-secures-5-1m-for-ai-powered-targeted-radiotherapy-for-cancer 2024-10-31T19:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/dbe3e33cca1f1b12/standout-breast-cancer-trial-outcomes-for-roche-small-molecule-therapy 2024-10-31T19:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/d7fee6ad5c82913b/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/968996561cf717ad/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/642ff6166d99cc3a/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/abc5e17f4475bc40/the-role-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-receiving-neoadjuvant-immune 2024-10-31T18:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/c4e9d4821457044b/new-phase-3-data-suggest-benefits-of-early-lecanemab-initiation-on-alzheimer-disease 2024-10-31T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/6b8d9a51038f3950/power-metals-high-grade-cesium-results-continue-in-latest-drilling-phase-junior-mining-network 2024-10-31T18:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/00727a90908f35da/genetic-test-predicts-survival-benefit-from-docetaxel-in-prostate-cancer-oncology-times 2024-10-31T17:46:16+00:00 weekly 0.7 https://trial.medpath.com/news/f2b576593350dc81/ninth-circuit-confirms-certain-stem-cell-products-require-fda-premarket-approval 2024-10-31T17:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/659e22cbe24ea52f/oral-and017-granted-orphan-drug-status-for-scd-sickle-cell-disease-news 2024-10-31T17:31:19+00:00 weekly 0.7 https://trial.medpath.com/news/16a783a7677a2a76/clinical-trial-shows-thrombectomy-does-not-improve-outcomes-for-patients-with-large-strokes 2024-10-31T17:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/542c9b449ec6442c/participant-motivations-key-to-success-in-clinical-trials-dermatology-times 2024-10-31T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/10ea73cc674c9b12/jancelewicz-co-principal-investigator-on-11-4-million-clinical-trial-grant-to-study 2024-10-31T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/8b179527476d81ba/defining-the-characteristics-of-breakthrough-invasive-fungal-infections-in-hematologic-disorders 2024-10-31T16:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/6f657ccc9dc7aebb/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-10-31T16:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/64368192f3a6a12f/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T16:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/078765457d6e7009/fda-fast-tracks-asciminib-for-new-chronic-leukemia-patients-webmd 2024-10-31T16:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/2bfb79ac626b7b52/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T16:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/a22fb585eb8c0771/cell-therapy-weekly-support-for-commercialization-of-complex-therapies-regmednet 2024-10-31T16:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/9ef319be15d77724/potentially-transformative-new-breast-cancer-drug-could-stop-disease-in-its-tracks-irish-star 2024-10-31T16:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/4dcb5020f2bcb2bf/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau-propagation-by-anti 2024-10-31T16:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/f82f4fa3332f89c4/vitamin-k2-reduces-dreaded-nighttime-leg-cramps-in-clinical-trial-medical-xpress 2024-10-31T16:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/0abb91ad87dba56d/court-upholds-fda-approval-of-avadel-s-narcolepsy-drug-lumryz-investing-com 2024-10-31T16:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/86f90129dc6ce6d7/sacituzumab-tirumotecan-nda-for-pretreated-egfr-nsclc-accepted-for-review-in-china 2024-10-31T16:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/391fc7d8ad244d7f/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma-the-asco-post 2024-10-31T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/c0304a7e701d5a9a/crispr-strategy-could-restore-delayed-onset-hearing-loss-drug-discovery-news 2024-10-31T16:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/531beeaf9f2b8e89/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:54:21+00:00 weekly 0.7 https://trial.medpath.com/news/b416e206db3bb44d/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer-clinical-trial-finds 2024-10-31T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/539171449f051176/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial-clinical-trials-arena 2024-10-31T15:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/c6bd75dfa64e8ea1/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/c07f9961edbcd051/crispr-cas13bt3-silences-vegfa-in-retinal-cells 2024-10-31T15:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/952cc24ccb833148/biogen-down-as-morgan-stanley-cuts-rating-on-sluggish-alzheimer-s-drug-launch 2024-10-31T15:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/d26f2bcfd8f18c42/evommune-raises-115m-to-accelerate-immune-drug-tests-biopharma-dive 2024-10-31T15:14:53+00:00 weekly 0.7 https://trial.medpath.com/news/693c1e8b86a83864/ovarian-cancer-produces-il-4-to-resist-immunotherapy-inside-precision-medicine 2024-10-31T15:12:29+00:00 weekly 0.7 https://trial.medpath.com/news/a5684d41231fc0fb/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/ab5300e32c6079c1/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/7332cddb895ac341/tuberculosis-how-close-are-we-to-a-new-vaccine-the-bmj 2024-10-31T15:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/53e71bb22e44b725/navigating-esr1-mutations-in-hr-positive-breast-cancer-with-dr-wander 2024-10-31T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/bc66412491d87fa9/compass-delays-pivotal-trial-readouts-for-psilocybin-in-depression-lays-off-30-of-staff 2024-10-31T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/214a0a1fb95c5e7a/genomic-screening-of-nyc-newborns-highlights-parent-s-interest-and-useful-findings 2024-10-31T14:53:09+00:00 weekly 0.7 https://trial.medpath.com/news/eb378ea703d99301/paclitaxel-or-sirolimus-coated-balloons-used-for-arteriovenous-fistulas-2-pave-2-trials 2024-10-31T14:49:53+00:00 weekly 0.7 https://trial.medpath.com/news/9feb00003ea5b865/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau 2024-10-31T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/ddaaf094563aace6/eisai-presents-data-on-benefits-of-long-term-administration-of-dual-acting-lecanemab-at 2024-10-31T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/news/54c9d4d969a03491/biofrontera-inc-announces-highly-significant-results-in-phase-3-study-of-ameluz-globenewswire 2024-10-31T14:41:11+00:00 weekly 0.7 https://trial.medpath.com/news/ef6d6e424d2a11bb/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial 2024-10-31T14:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/05cac43850dfb62c/fda-clears-second-set-of-changes-to-irhythm-zio-at-to-resolve-warning-letter-massdevice 2024-10-31T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/23d6f57496c65cf8/shanghai-henlius-biotech-organon-announce-fda-acceptance-of-bla-for-hlx14 2024-10-31T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/0111949db3fae88a/phase-3-interpath-009-trial-of-mrna-4157-plus-pembrolizumab-for-nsclc-begins-recruitment 2024-10-31T14:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/16297078a4ddb0d5/pharmadrug-s-sairiyo-therapeutics-announces-successful-completion-of-stability-study-of 2024-10-31T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/bff2d7137e505630/ventus-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-of-vent 2024-10-31T13:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/53fd2be2b6d4357d/recce-pharmaceuticals-announces-interim-efficacy-data-and-safety-approval-for-phase-ii 2024-10-31T13:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/02a129838138331c/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-biospace 2024-10-31T13:58:03+00:00 weekly 0.7 https://trial.medpath.com/news/965b01d4dfdff498/capricor-therapeutics-and-the-fda-a-daring-risky-filing-strategy-stat-news 2024-10-31T13:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/d1826339fb87a262/advanced-therapies-redefine-survival-for-patients-with-breast-cancer-pharmacy-times 2024-10-31T13:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/304bf2e609f3a2f9/nih-study-demonstrates-long-term-benefits-of-weight-loss-surgery-in-young-people 2024-10-31T13:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/0472ce41e2156b5c/the-semaglutide-drought-may-be-ending-stat-news 2024-10-31T13:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/48d9bd9bd5dd638b/compass-cuts-30-of-staff-as-late-stage-psilocybin-drug-trials-face-new-delays 2024-10-31T13:32:35+00:00 weekly 0.7 https://trial.medpath.com/news/3c3371c7cb9e63b8/new-breast-cancer-therapy-doubles-progression-free-survival-pf-media 2024-10-31T13:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/fa0215f28e8de586/study-suggests-earlier-is-better-for-heart-valve-replacement-procedures 2024-10-31T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/9f4557d589bfc3ef/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T13:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/e02b510c6a659b3a/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/104978effb3b8a7a/leo-pharma-continues-to-deliver-double-digit-revenue-growth-backed-by-strong-dermatology-sales 2024-10-31T13:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/098b42872a8fb81f/naya-biosciences-to-present-translational-insights-to 2024-10-31T13:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/4503f038fccb6f33/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-stock-titan 2024-10-31T12:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/5a7284a3c2357bcd/uk-dementia-clinical-trial-participation-set-to-boost-by-tens-of-thousands-pharmatimes 2024-10-31T12:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/75da7cf3e6e5e220/us-fda-grants-accelerated-approval-to-novartis-scemblix-for-adult-patients-with-newly 2024-10-31T12:29:31+00:00 weekly 0.7 https://trial.medpath.com/news/6a30d132aea5dadc/acumen-pharmaceuticals-presents-innovative-trial-screening-advancements-morningstar 2024-10-31T12:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/0ff6da2fa0a36159/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/de54df45cfba598a/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/0a7abb97279e00f9/high-grade-cesium-results-continue-in-latest-drilling-phase-canada-newswire 2024-10-31T12:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/8c3be4ea3f18ca31/alloplex-s-cancer-immunotherapy-shows-promise-in-phase-i-trial 2024-10-31T12:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/114f2a2e6d05b1c5/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-in-cd70 2024-10-31T12:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/6948b0d2cb8b3326/medidata-launches-bundled-solutions-to-support-oncology-and-vaccine-trials 2024-10-31T12:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/775a9196711489c1/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti 2024-10-31T11:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/518a8ffef25d4781/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti-placera 2024-10-31T11:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/f6cd2f0a126e48f2/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T11:39:03+00:00 weekly 0.7 https://trial.medpath.com/news/5f05826528a48ae6/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/34e76196e74cf4b6/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/0329939ee807cc21/avadel-pharmaceuticals-announces-favorable-ruling-in-administrative-procedure-act-litigation 2024-10-31T11:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/a4c3a373ae6aa58c/appili-therapeutics-announces-alignment-with-fda-on-globenewswire 2024-10-31T11:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/2442d2bfcae6d791/madrigal-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-10-31T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/842d7532f1587649/breast-cancer-breakthrough-as-new-drug-combination-stops-disease-in-its-tracks 2024-10-31T11:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/64181d8826041db8/avadel-pharmaceuticals-announces-favorable-ruling-in-globenewswire 2024-10-31T11:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/cb8faebe1e8e72c3/fda-grants-accelerated-approval-for-leukemia-treatment-becker-s-hospital-review 2024-10-31T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/b64228e739d77ffc/personalized-neuromodulation-treatment-significantly-slowed-alzheimer-s-progression-in 2024-10-31T11:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/5c2078dffc011ccf/syros-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-10-31T10:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/ee9c0651004b2214/compass-pathways-plc-sec-10-q-report-tradingview 2024-10-31T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/a7e928b8978e1f6e/curevo-presents-positive-shingles-vaccine-outcomes-data 2024-10-31T10:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/e63a68b713a4a26d/retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine-breakthrough 2024-10-31T10:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/19fafef85025c1f0/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/ff726f4f67c04ecb/first-site-initiated-in-australia-for-mannkind-s-phase-3-clinical-trial-evaluating-clofazimine 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/cdf21d2c8878ca7d/corcept-therapeutics-announces-third-quarter-financial-results-positive-results-biospace 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/d2b21aebcdfbf31d/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-31T09:48:45+00:00 weekly 0.7 https://trial.medpath.com/news/447dbf19a53182c8/noema-pharma-announces-first-patients-dosed-in-phase-2b-study-with-gemlapodect-noe 2024-10-31T09:48:44+00:00 weekly 0.7 https://trial.medpath.com/news/bf2c5a45211ff37f/t-cell-malignancies-clinical-trial-pipeline-insights-featuring-70-companies-delveinsight 2024-10-31T09:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/dde4870ecc2b7240/jpmorgan-sees-cipla-stock-upside-as-fda-approval-accelerates-gabraxane-launch 2024-10-31T09:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/d30b947e2614860d/daiichi-sankyo-astrazeneca-launch-phase-iii-trials-of-datopotamab-deruxtecan-in 2024-10-31T09:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/a17e3434cebe762f/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-10-31T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/b143585334e14a9d/a-one-week-elderberry-juice-intervention-augments-the-fecal-microbiota-and-suggests-pubmed 2024-10-31T09:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/05418805e7bbfb44/protega-pharma-receives-us-fda-approval-for-roxybond-ir-10-mg-tablet-with-abuse 2024-10-31T08:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/aa96c3c96cc810f7/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T08:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/41c209af65e82f71/fda-grants-accelerated-approval-of-scemblix-for-newly-diagnosed-cml 2024-10-31T07:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/a79fcb6f28281448/biofuture-2024-fda-eases-the-way-for-cell-and-gene-therapy-companies-bioworld 2024-10-31T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/f2f7b7fd422d35a9/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/e3fe3b136b513c2f/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-sharecafe 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/be0bcaa004ef9e60/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-31T06:45:58+00:00 weekly 0.7 https://trial.medpath.com/news/d3bcfa6333e66fe7/optiscan-doubles-revenue-boosts-profit-for-sep-qtr-brisbane-times 2024-10-31T06:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/c8eb947fd61bec9e/chugai-files-for-additional-indication-of-tecentriq-for-the-treatment-of-extranodal-natural 2024-10-31T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/2a91da09ebb484da/takeda-announces-strong-first-half-fy2024-results-and-raises-full-year-outlook 2024-10-31T06:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/3d87834df1f3812c/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:14:12+00:00 weekly 0.7 https://trial.medpath.com/news/3146ff07528203f9/ttvr-with-evoque-device-linked-to-substantial-benefits-after-1-year 2024-10-31T06:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/44f2f3920bf494e6/company-announcement-ft-com-markets-data 2024-10-31T06:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/bea3fc42be3c30d8/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/23f04d85f8f7e405/new-three-drug-therapy-could-double-breast-cancer-survival-time-yahoo 2024-10-31T05:47:40+00:00 weekly 0.7 https://trial.medpath.com/news/2b1bb2e858361c0b/fda-regulations-evolve-as-science-changes-elevar-therapeutics-coo-kbr 2024-10-31T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/48486aef54567b77/cstone-announces-mhra-approval-of-sugemalimab-for-first-line-treatment-of-non-small 2024-10-31T05:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/c0290ae33ea10a07/multidisciplinary-teams-transform-stage-3a-lung-cancer-care-with-precision-medicine-approach 2024-10-31T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/54f350d4a8e9ea89/shuttle-pharma-doses-three-subjects-in-phase-ii-glioblastoma-treatment-trial 2024-10-31T04:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/3dfe04b2774e6574/acurate-ide-trial-misses-primary-endpoint-in-all-risk-tavi-patients-tctmd-com 2024-10-31T04:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/e16b1ef9f1ae7104/cipla-shares-rise-10-after-usfda-paves-way-for-abraxane-drug-launch-news18 2024-10-31T04:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/f97335d9754e799c/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimers-disease-in-phase-2a-study-at-ctad-2024 2024-10-31T04:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/f3909357920945db/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T04:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/826ec4e15e4fa9bd/new-vaccine-production-process-could-help-in-health-emergencies 2024-10-31T04:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/0137d784987ca14d/sichuan-kelun-biotech-s-promising-drug-gains-key-approval-markets-insider 2024-10-31T03:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/93c999e40f76f180/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T03:57:26+00:00 weekly 0.7 https://trial.medpath.com/news/32b480945fded82b/fda-didn-t-flub-approval-in-orphan-drug-case-dc-court-says-law360-uk 2024-10-31T03:50:19+00:00 weekly 0.7 https://trial.medpath.com/news/16fed951db32558a/acurate-neo2tm-aortic-valve-system-data-presented-at-late-breaking-clinical-trial 2024-10-31T03:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/22ea4a96b2094752/medable-and-google-cloud-partner-to-revolutionize-digital-clinical-trial-platform-access 2024-10-31T03:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/d351e49c2323e76b/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-plus-defactinib-as-a-treatment-for-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-10-31T03:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/594ae31b5fa0efc3/2024-ncoda-summit-highlights-advances-in-cancer-care-and-treatment-innovation 2024-10-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/36f4aa2ec2f29120/l-k-biomed-earns-fda-approval-for-new-lumbar-spine-device 2024-10-31T02:51:40+00:00 weekly 0.7 https://trial.medpath.com/news/26e0367c4f9bfd75/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis-morningstar 2024-10-31T02:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/38ce88d2206f908d/clofutriben-shows-promise-in-trial-for-endogenous-cushing-s-syndrome 2024-10-31T02:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/521f21687b79c024/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T02:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/b8a48fe088eb4319/nature-cell-s-jointstem-receives-fda-rmat-designation-hiteunyuseu 2024-10-31T02:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/6d8e796635e6c26a/cutia-therapeutics-announces-trial-success-for-fat-reduction-drug-markets-insider 2024-10-31T02:16:39+00:00 weekly 0.7 https://trial.medpath.com/news/d793ff9fa3a1bd02/c-o-r-r-e-c-t-i-o-n-akeso-inc-company-announcement-ft-com-markets-data 2024-10-31T01:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/86e4c7a0c8722dbd/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-finance-news-network 2024-10-31T01:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/a43aa9b5618add2a/advancing-alzheimer-treatment-through-gamma-oscillation-stimulation-ralph-kern-md-mhsc 2024-10-31T01:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/b5ab2f39f357571f/pembrolizumab-plus-chemotherapy-enhances-outcomes-in-early-stage-tnbc 2024-10-31T01:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/c7fe7a283cd841ca/it-was-a-revolution-the-forgotten-australian-whose-medical-breakthrough-saved-millions-of-lives 2024-10-31T01:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/9050a58bc9a2d424/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combined-with 2024-10-31T00:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/c55a3f1faca50e54/nda-submitted-for-3-month-formulation-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-31T00:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/4f666f73270022fa/three-drug-treatment-for-breast-cancer-can-delay-the-spread-of-disease-daily-mail 2024-10-31T00:35:06+00:00 weekly 0.7 https://trial.medpath.com/news/158e63a9a678ce16/fda-expands-approval-for-shorla-s-jylamvo-for-paediatric-patients 2024-10-31T00:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/3b5e553bea608b82/triumvira-immunologics-to-present-new-clinical-data-from-ongoing-claudin-18-2-phase-1 2024-10-31T00:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/57ec9bc70e63daef/eisai-presents-data-on-benefits-of-long-term-administration-globenewswire 2024-10-30T23:39:26+00:00 weekly 0.7 https://trial.medpath.com/news/75bff075b617fffc/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-quantisnow 2024-10-30T23:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/73a3a75bdb944d6a/eli-lilly-shares-positive-phase-iii-data-of-mirikizumab-for-the-treatment-of-crohn-s-disease 2024-10-30T23:24:37+00:00 weekly 0.7 https://trial.medpath.com/news/5eb636847101d29c/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-globenewswire 2024-10-30T23:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/cae52735337caa22/novartis-secures-first-line-cml-expansion-for-scemblix-projects-3b-in-peak-sales 2024-10-30T23:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/66cc0b4df60d5d5c/fda-staff-not-quite-sold-on-sotagliflozin-for-t1d-patients-with-ckd-medpage-today 2024-10-30T23:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/261086cec23e09c3/new-hope-for-breast-cancer-patients-after-huge-therapy-breakthrough-mirror-online 2024-10-30T22:59:31+00:00 weekly 0.7 https://trial.medpath.com/news/b4ca63a082e7f1de/leukemia-drug-shows-promise-in-dementia-with-lewy-bodies-medpage-today 2024-10-30T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/629dfff3aa8046fc/three-drug-mix-doubles-survival-time-for-advanced-breast-cancer-the-times 2024-10-30T22:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/c1b563010eb612d2/karyopharm-to-host-investor-event-with-leading-myelofibrosis-kols-and-provide-a 2024-10-30T22:30:28+00:00 weekly 0.7 https://trial.medpath.com/news/e529b66eb2ce6034/fda-issues-warning-on-biozorb-markers-after-recall-due-to-patient-complications 2024-10-30T22:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/9008324aaf722790/intravesical-mitomycin-demonstrates-significant-duration-of-response-in-nmibc 2024-10-30T22:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/924e292acc7e15db/phase-ii-study-of-upar-pet-ct-for-staging-of-primary-breast-cancer-in-comparison-with 2024-10-30T22:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/598e8c39e65e9f99/phase-3-trailrunner-alz-3-to-test-effects-of-igg1-monoclonal-antibody-remternetug-in 2024-10-30T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/f7ccb9c847d6d098/3-to-know-nch-partners-for-clinical-trials-student-dies-more-marco-eagle 2024-10-30T22:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/c39f1b43ce6ad1ff/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/0dec50f640f21943/irhythm-technologies-receives-fda-510-k-clearance-for-design-modifications-to-its-zio 2024-10-30T21:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/c83b4f5c11cdc6c3/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/21e48c826c085169/huge-breakthrough-in-breast-cancer-drug-therapy-doubles-survival-time-the-independent 2024-10-30T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/2d79e853c10dbb32/lexeo-therapeutics-scores-positive-early-data-for-apoe4-alzheimer-s-gene-therapy 2024-10-30T21:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/31deb4e899b1732c/breast-cancer-survival-time-doubles-with-three-drug-therapy-trial-finds-the-telegraph 2024-10-30T21:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/e655352c743f8aaf/wegovy-reduces-knee-pain-in-osteoarthritis-patients-with-obesity-study-finds-stat-news 2024-10-30T21:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/95eaae248201901f/medtronic-receives-fda-approval-of-mapping-and-ablation-system-and-catheter-daic 2024-10-30T20:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/0e8e429fefbd903e/fda-advises-against-use-of-biozorb-markers-in-breast-cancer-and-other-indications 2024-10-30T20:51:11+00:00 weekly 0.7 https://trial.medpath.com/news/cae52467c12ca61d/fda-receives-nda-for-3-month-version-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-30T20:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/e84e19cc14f2cc90/wave-life-sciences-highlights-growing-pipeline-at-research-globenewswire 2024-10-30T20:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/b08a66adfd9ff8f8/risk-of-aria-e-in-donanemab-attenuated-through-new-enhanced-titration-method-of-delivery 2024-10-30T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/e4c8e8ec4495b9ef/neurovoices-anne-marie-morse-do-faasm-on-the-impact-of-the-once-nightly-sodium 2024-10-30T20:44:36+00:00 weekly 0.7 https://trial.medpath.com/news/ef3d40a7eed59230/azenta-obtains-regulatory-approval-for-clinical-long-read-whole-genome-sequencing-test 2024-10-30T20:33:46+00:00 weekly 0.7 https://trial.medpath.com/news/f6bc177841de2e34/doctor-given-24-months-to-live-reveals-how-she-reversed-her-cancer-with-breakthrough-therapy 2024-10-30T20:19:31+00:00 weekly 0.7 https://trial.medpath.com/news/dbe7782d6c3e1ea2/fda-approves-abbott-cgms-for-use-during-medical-imaging-drug-delivery-business 2024-10-30T20:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/0df2e352af88b9b7/galapagos-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-10-30T20:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/0e4d7dc0d9a6d236/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-30T20:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/746805562e09d124/fda-approves-another-new-antibiotic-becker-s-hospital-review 2024-10-30T20:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/45247cc35570584a/new-insights-in-cancer-care-shared-at-annual-oncology-update-2024-inventum 2024-10-30T20:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/3658d5672db97c4a/biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd 2024-10-30T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/a6b8052bce0b062d/with-fresh-funding-houston-cancer-fighting-cell-therapy-gears-up-for-continued-clinical-trials 2024-10-30T19:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/9f3b2d76174e79ab/low-dose-dobutamine-in-acute-myocardial-infarction-with-intermediate-to-high-risk-of-trials 2024-10-30T19:42:46+00:00 weekly 0.7 https://trial.medpath.com/news/e71997c97964885f/ohsu-researchers-identify-gene-that-could-be-key-to-future-hiv-vaccine 2024-10-30T19:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/a7a10755cab259c3/mineralys-therapeutics-completes-enrollment-ahead-of-schedule-in-launch-htn-the-biospace 2024-10-30T19:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/36a2edac4717d9fa/fda-accepts-biologic-license-application-for-biosimilar-denosumab-pharmacy-times 2024-10-30T19:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/fa0307d374ac9fa3/october-2024-fda-approvals-for-oncology 2024-10-30T19:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/9be6b906dbd078c5/novartis-scemblix-secures-fda-accelerated-approval-for-chronic-myeloid-leukaemia 2024-10-30T18:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/41cd9625705356c0/how-cidara-got-its-molecule-back-life-science-leader 2024-10-30T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/d481ec9cbb0cdb55/health-rounds-adaptable-implant-may-be-improvement-over-heart-stents 2024-10-30T18:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/951d672c14133b07/swiss-moves-and-approvals-national-bank-and-novartis-steal-the-show-finimize 2024-10-30T18:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/b0dbd4f8529464bf/fda-grants-accelerated-approval-to-asciminib-for-chronic-myeloid-leukemia-healio 2024-10-30T18:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/6b0e363d91d6b428/fda-expands-jylamvo-approval-to-include-polyarticular-juvenile-idiopathic-arthritis-all 2024-10-30T18:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/29a149ca42c6203a/ready-to-use-3-month-leuprolide-depot-formulation-nears-fda-approval 2024-10-30T18:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/efae1c5b8d48c372/boston-scientific-acurate-neo2-tavr-misses-primary-endpoint-in-ide-trial-massdevice 2024-10-30T18:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/c6301e18cda0499d/uproleselan-combo-does-not-improve-efs-vs-chemo-in-newly-diagnosed-aml 2024-10-30T18:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/10fdb1e2677aad9f/a-collaborative-approach-to-pancreatic-cancer-michigan-medicine 2024-10-30T18:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/37ce3d75f77cf5e9/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomarker 2024-10-30T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/ad6edd55d3403717/heartlung-ai-tool-receives-fda-breakthrough-ai-clearance-daic 2024-10-30T17:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/ba18bf4172d14657/fda-approves-protega-s-roxybond-10-mg-abuse-deterrent-opioid-contract-pharma 2024-10-30T17:56:50+00:00 weekly 0.7 https://trial.medpath.com/news/613f96009f816af0/fda-approves-first-anti-tfpi-antibody-for-haemophilia-a-and-b-nature 2024-10-30T17:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/f275c77ce55a619a/fda-approves-pi3ka-inhibitor-that-does-double-duty-as-a-degrader-nature 2024-10-30T17:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/2dde932ba14d258b/eli-lilly-plans-to-begin-advertising-weight-loss-drug-zepbound-yahoo-finance 2024-10-30T17:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/7edffd63d187de07/histomonosis-a-deadly-turkey-disease-researched-with-new-3-2-million-fda-grant 2024-10-30T17:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/49bf14b4ff3b6713/tropion-lung01-update-dato-dxd-shows-activity-in-previously-treated-advanced 2024-10-30T16:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/e9943cd36858469c/novartis-gets-fda-okay-for-frontline-use-of-scemblix-in-cml-pharmaphorum 2024-10-30T16:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/19c5f6ebf41969e1/small-molecule-drug-triggers-rapid-cell-death-in-cancer-models-medical-xpress 2024-10-30T16:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/fcb13c40f8732961/south-west-researchers-seek-participants-for-flu-vaccine-trial-ivybridge-today 2024-10-30T16:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/c0c66bf22cae8f53/active-biotech-s-tasquinimod-study-receives-green-light-from-ema-marketscreener 2024-10-30T16:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/212a8975c4f83cb3/fda-grants-accelerated-approval-to-novartis-scemblix-for-newly-diagnosed-chromosome 2024-10-30T16:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/b182a81ce28fae1d/sure1-and-reassure-trials-paved-way-for-fda-approval-of-orlynvah-contagion-live 2024-10-30T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/6e016e187886ce8e/a-virtual-breakthrough-series-collaborative-for-missed-test-results-jama-network 2024-10-30T15:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/748ce9e9fa89ca6b/neurosense-fda-to-meet-on-phase-3-plans-for-primec-in-als-als-news-today 2024-10-30T15:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/3dced576b6450f29/latest-updates-of-viva-biotech-s-portfolio-companies-morningstar 2024-10-30T15:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/481576b922dcd00a/novel-treatment-options-for-children-and-young-adults-with-relapsed-osteosarcoma 2024-10-30T15:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/d09f2863e64d1739/methotrexate-s-approval-expanded-to-include-pediatric-all-oncology-nursing-news 2024-10-30T15:09:45+00:00 weekly 0.7 https://trial.medpath.com/news/aa84a9d6cce56e93/triscend-ii-trial-demonstrates-superior-clinical-and-quality-of-life-benefits-with-edwards 2024-10-30T15:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/eaabfee1709d7ff5/early-data-from-roche-s-alzheimer-s-therapy-show-it-s-hitting-targets-stat-news 2024-10-30T14:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/a57449d2bfa1d8e1/tharimmune-receives-positive-regulatory-feedback-from-ema-for-th104-clinical-program 2024-10-30T14:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/452155afd4a52252/new-treatment-shrinks-man-s-aggressive-brain-tumour-by-half-in-breakthrough-trial 2024-10-30T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/78b3da7004e6e7a6/use-of-aumolertinib-extends-progression-free-survival-in-stage-iii-egfr-mutated-nsclc 2024-10-30T14:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/2788d2ab41726d33/fasenra-granted-approval-in-eu-for-hard-to-treat-egpa-patients-anca-vasculitis-news 2024-10-30T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/a184201621a22177/can-roswell-park-s-promising-brain-cancer-vaccine-work-for-children-and-young-adults 2024-10-30T13:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/36b0fad01d470562/biomea-awaits-2-data-readouts-of-diabetes-studies-can-the-stock-get-its-mojo-back 2024-10-30T13:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/c700276195c65ccc/abbvie-acquires-aliada-and-alzheimer-s-candidate-for-1-4b-inside-precision-medicine 2024-10-30T13:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/a171fb3feb3bed57/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-globenewswire 2024-10-30T13:53:36+00:00 weekly 0.7 https://trial.medpath.com/news/89891b9bea26d365/scilex-announces-successful-end-of-phase-ii-meeting-with-fda-markets-insider 2024-10-30T13:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/f4c0b0d3dfdbbc9c/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial-yahoo-finance 2024-10-30T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/df9dbf56471f524b/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial-pharmaceutical-technology 2024-10-30T13:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/5f21128c3179a902/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-newly-diagnosed-ovarian 2024-10-30T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/91cdc1f8a4440d41/new-fda-approved-approach-to-treating-liver-cancer-kplc 2024-10-30T13:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/9c4492c3008d4e3d/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial 2024-10-30T13:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/d69d91a30b427f93/sagimet-s-denifanstat-enters-phase-iii-trials-for-mash-treatment 2024-10-30T13:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/b164d4dcf9345652/zai-lab-presents-positive-outcomes-from-karxt-phase-iii-trial-for-schizophrenia 2024-10-30T13:00:55+00:00 weekly 0.7 https://trial.medpath.com/news/9e2d771fb562188c/tharimmune-receives-positive-regulatory-feedback-from-ema-for-th104-clinical-program 2024-10-30T12:54:20+00:00 weekly 0.7 https://trial.medpath.com/news/cf1701c65f2037a0/beta-bionics-launches-ilet-pump-with-abbott-freestyle-libre-3-plus 2024-10-30T12:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/a206665faa168a15/cytodyn-appoints-dr-melissa-palmer-m-d-as-lead-consultant-in-hepatology 2024-10-30T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/993d71e291ed3395/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-30T12:48:01+00:00 weekly 0.7 https://trial.medpath.com/news/f6a315332befa963/a-doctor-weighs-in-on-anti-agers-using-rapamycin-to-extend-their-lives-cnbc 2024-10-30T12:47:11+00:00 weekly 0.7 https://trial.medpath.com/news/1f01084d0024ac78/sagimet-s-denifanstat-enters-phase-iii-trials-for-mash-treatment-yahoo-finance 2024-10-30T12:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/1d8121a7a7d74c32/synox-therapeutics-adds-new-investor-and-capital-to-series-b-financing-raising-total-to 2024-10-30T12:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/815f7ef8999efdda/tiziana-life-sciences-announces-positive-results-from-globenewswire 2024-10-30T12:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/59e84ab2691c1914/promis-neurosciences-presents-positive-data-from-pmn310-phase1a-clinical-trial-morningstar 2024-10-30T12:30:38+00:00 weekly 0.7 https://trial.medpath.com/news/ed42e03141e3f293/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients 2024-10-30T12:30:12+00:00 weekly 0.7 https://trial.medpath.com/news/771ab61fa5b848c4/avidity-biosciences-advances-fshd-therapy-trial-by-investing-com 2024-10-30T12:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/b66f4a72815e4e76/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-biospace 2024-10-30T12:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/1740864b201991b9/promis-neurosciences-presents-positive-data-from-pmn310-globenewswire 2024-10-30T12:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/a57de865e9f73bab/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomarker 2024-10-30T12:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/cadfedf173d45421/hamlet-biopharma-interview-with-chairman-professor-catharina-svanborg-about-the-pulse-2-0 2024-10-30T12:05:29+00:00 weekly 0.7 https://trial.medpath.com/news/6dee40b94bea0b6a/dassault-systemes-collaboration-yields-breakthrough-guide-for-using-virtual-twins-in-clinical-trials 2024-10-30T12:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/50954b0b140f94ae/summit-therapeutics-reports-operational-progress-and-financial-results-for-the-morningstar 2024-10-30T11:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/5406d94f1a4d4be5/evan-dellon-md-mph-promising-phase-3-cendakimab-data-for-eosinophilic-esophagitis 2024-10-30T11:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/444f2ee6584ae0f7/tissue-agnostic-cancer-therapies-herald-new-era-in-precision-oncology-expert-says 2024-10-30T11:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/6b8b30b252b3fe16/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-10-30T11:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/ebd5f3cebe9179f7/ananda-developments-interims-for-the-six-months-ended-31-july-2024-research-tree 2024-10-30T11:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/4fb038a1801a72dd/synox-therapeutics-adds-new-investor-and-capital-to-series-globenewswire 2024-10-30T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/b4b414361bdfa6ba/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-10-30T11:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/538915e6940c9313/novartis-scemblix-gains-fda-approval-for-leukaemia-treatment 2024-10-30T10:52:13+00:00 weekly 0.7 https://trial.medpath.com/news/690eff4f2f60e3fc/gsk-on-track-to-deliver-2024-outlooks-with-further-good-progress-made-in-r-d 2024-10-30T10:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/162f95273308992a/evaluating-a-multicomponent-intervention-for-managing-kidney-outcomes-among-patients-trials 2024-10-30T10:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/6fa2ade07b8c258a/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-morningstar 2024-10-30T10:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/beb99ae2cc98ad89/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-stock-titan 2024-10-30T10:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/86bddbcc81da8091/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-globenewswire 2024-10-30T10:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/33e9845c41f4007c/active-biotech-s-clinical-trial-of-tasquinimod-in-myelofibrosis-approved-in-europe-placera 2024-10-30T09:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/6afa4ad1a7dd67f1/chop-receives-10-million-grant-for-project-that-uses-clinical-data-analysis-to-combat-rare-diseases 2024-10-30T09:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/bdf1a87209aa21f2/a-prospective-open-label-phase-iib-iii-study-to-evaluate-the-risk-of-tls-and-optimization 2024-10-30T09:40:40+00:00 weekly 0.7 https://trial.medpath.com/news/9a4700f3f439eb0b/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat 2024-10-30T09:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/15321710a6e8222d/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-30T09:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/39ba73cdf9774588/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-with-its-fibrin 2024-10-30T09:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/6751f94665575f54/roche-and-dyno-therapeutics-form-1b-alliance-to-develop-ai-powered-gene-therapies-for-neurological-disorders 2024-10-30T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/d298e34718c2f9f0/insights-for-psychedelic-stakeholders-from-recent-fda-public-meeting-on-advancing-lexology 2024-10-30T08:48:17+00:00 weekly 0.7 https://trial.medpath.com/news/3f62391220f1fd73/biotech-stocks-facing-fda-decision-in-november-2024-rttnews 2024-10-30T08:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/d477044466ea0269/methotrexate-gains-expanded-approval-for-pediatric-acute-lymphoblastic-leukemia 2024-10-30T08:36:08+00:00 weekly 0.7 https://trial.medpath.com/news/a3355b42b8776cfc/pharmaceutical-industry-faces-widespread-layoffs-amid-patent-cliffs-and-economic-uncertainty 2024-10-30T08:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/042566d2f4b91214/gsk-plc-confirms-2024-guidance-q3-dividend-of-15p-declared-directorstalk-interviews 2024-10-30T08:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/e10db3639b2ab0bc/astellas-withdraws-izervay-s-european-approval-filing 2024-10-30T08:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/dc7c525edc3ac686/october-30-2024-in-this-week-s-pct-grand-rounds-the-chi-ron-study-of-adults-with 2024-10-30T08:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/431f49de8bd3e6bd/medidata-cogstate-partner-to-transform-clinical-trials-in-neurology-bernama 2024-10-30T07:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/33512cd89d9494dc/novel-therapies-transform-treatment-landscape-for-liver-and-biliary-tract-cancers 2024-10-30T07:33:31+00:00 weekly 0.7 https://trial.medpath.com/news/7c61d7e92384c877/novartis-scemblix-r-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and 2024-10-30T07:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/a92a2fc67b3a9a77/gsk-reports-sharp-decline-in-vaccine-sales-as-rsv-shot-arexvy-falls-72-in-q3 2024-10-30T07:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/71b7d13107280fce/a-better-drug-may-make-transplants-more-successful-yahoo 2024-10-30T06:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/9b3623889651244d/patient-researcher-s-journey-leads-to-breakthrough-treatment-for-rare-light-sensitivity-disorder 2024-10-30T06:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/adc08bd3eff27a23/inari-medical-s-flowtriever-meets-primary-endpoint-in-pulmonary-embolism-trial 2024-10-30T06:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/4cc94eaf5219f6e4/irlab-publishes-interim-report-for-the-period-january-september-2024-morningstar 2024-10-30T06:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/b0a033dacbd6f069/researchers-begin-phase-3-trial-assessing-adjuvant-v940-with-pembrolizumab-to-treat 2024-10-30T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/af9429ce6673ae40/well-health-and-healwell-ai-work-to-expand-clinical-trial-access-mugglehead-magazine 2024-10-30T05:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/7441e6177e98ee8f/ptc-therapeutics-announces-fda-acceptance-of-translarna-nda-resubmission 2024-10-30T05:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/f0ab03cc45668cbf/evolution-of-precision-medicine-reshapes-cancer-treatment-landscape-expert-highlights-future-of-blood-based-monitoring 2024-10-30T05:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/175d637a7fbc1724/usp-standards-and-engineering-controls-essential-for-safe-hazardous-drug-compounding 2024-10-30T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/293d476fedbac036/adagrasib-in-krystal-12-has-broken-the-krasg12c-enigma-code-in-non-sma-lctt 2024-10-30T04:44:57+00:00 weekly 0.7 https://trial.medpath.com/news/949f45ab5490cb0e/dr-dhakal-on-notable-multiple-myeloma-trials-presented-in-2024-onclive 2024-10-30T04:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/056db1cb9b460225/novartis-scemblix-receives-accelerated-fda-approval-for-newly-diagnosed-ph-cml-in-adults 2024-10-30T04:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/a6ee930061d454b4/abbvie-to-acquire-biotechnology-company-aliada-therapeutics-for-1-4-billion-pharmabiz 2024-10-30T03:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/5c77bc90ba53bd46/epilepsy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-30T03:18:21+00:00 weekly 0.7 https://trial.medpath.com/news/d772be68135ed16d/ynhh-performs-first-fda-approved-tambe-procedure-in-connecticut-yale-daily-news 2024-10-30T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/74724f153b47ed02/fda-expands-approval-for-jylamvo-to-children-with-acute-lymphoblastic-leukemia 2024-10-30T03:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/987b5bb6cef34c60/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-10-30T03:10:02+00:00 weekly 0.7 https://trial.medpath.com/news/b1f4f7a1bd6786b6/monte-rosa-novartis-partner-to-advance-molecular-glue-degraders-contract-pharma 2024-10-30T03:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/48c97d92e84095bc/first-participants-dosed-in-trial-of-long-acting-malaria-preventative-clinical-trials-arena 2024-10-30T02:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/6c532c2281209d5e/biogen-raises-2024-earnings-outlook-as-new-drug-portfolio-shows-promise 2024-10-30T02:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/cb6c4e97e1656363/shuttle-pharmaceuticals-holdings-inc-announces-pricing-of-4-5-million-public-offering 2024-10-30T01:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/c315b60abfe65757/novartis-scemblix-r-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and 2024-10-30T01:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/ded3651877c3ae16/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies 2024-10-30T01:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/90967bb0283f862e/study-shows-dedicated-prior-authorization-teams-and-care-management-homes-accelerate-ibd-treatment-access 2024-10-30T01:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/cc39aca4d3fc0e69/biofuture-2024-charting-the-future-for-glp-1s-bioworld 2024-10-30T00:52:58+00:00 weekly 0.7 https://trial.medpath.com/news/3c97dbfd130a24ac/coya-sinks-on-phase-ii-alzheimer-s-data-advances-combo-strategy-bioworld 2024-10-30T00:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/4eacc08bfcc0242c/fda-approves-new-dose-for-abuse-deterrent-oxycodone-healio 2024-10-30T00:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/81ec20f96adadf83/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer 2024-10-30T00:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/277163c539e8b488/machine-learning-optimizes-non-invasive-brain-stimulation-for-depression-treatment 2024-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9334ee23ecd4521c/fda-approves-protega-pharmaceuticals-roxybond-for-severe-pain-management 2024-10-29T23:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/719171c861121499/data-driven-approaches-to-accelerate-clinical-trial-diversity-astrazeneca 2024-10-29T23:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/0d997bed7ad9898c/actuate-to-participate-in-lantern-s-pharma-webinar-on-ai-driven-drug-development 2024-10-29T22:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/211990e6f49290ee/biopharma-co-escapes-investor-suit-over-drug-approval-lies-law360 2024-10-29T22:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/92170c265ed43ecd/novel-drug-for-chronic-inducible-urticaria-delivers-in-mid-stage-trial-medpage-today 2024-10-29T22:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/d387bbe739f68e02/elixir-medical-has-positive-data-for-drug-eluting-bioadaptive-implant-massdevice 2024-10-29T22:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/b51f49fe64cd82c5/sonablate-enrolls-first-patient-in-incompetent-vein-ablation-clinical-trial-massdevice 2024-10-29T22:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/0f0e859b074a9610/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies-of-rezpegaldesleukin-in-two-inflammatory-skin-diseases 2024-10-29T22:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/3b1e29fc73977776/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-u-s-food-and-drug-administration 2024-10-29T22:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/2f97f6978a9efa0c/nccn-guideline-update-recommends-adjuvant-ribociclib-plus-ai-in-hr-her2-onclive 2024-10-29T22:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/7e967a65d6ac9cea/first-patient-takes-part-in-new-phase-1-clinical-trial-for-patients-with-recurrent-glioblastoma 2024-10-29T21:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/c3a3b2c681465c8c/colchicine-falls-flat-in-large-heart-attack-trial-convincing-cardiologists-to-stay-away 2024-10-29T21:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/659e090881cce8aa/lexicon-s-sotagliflozin-returns-to-us-fda-panel-with-narrowed-indication 2024-10-29T21:29:55+00:00 weekly 0.7 https://trial.medpath.com/news/dab920522c0a28f0/fda-grants-accelerated-approval-to-asciminib-in-ph-cml-in-chronic-phase-cancer-network 2024-10-29T20:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/b44dcb6fa26d94cd/invivyd-announces-phase-3-exploratory-clinical-efficacy-data-regarding-pemgarda-prel 2024-10-29T20:55:56+00:00 weekly 0.7 https://trial.medpath.com/news/d4db0869b313dbb1/newsweek-s-top-dfw-hospitals-and-tcu-and-uta-s-joint-md-phd-program-d-magazine 2024-10-29T20:54:02+00:00 weekly 0.7 https://trial.medpath.com/news/5fe2c0cecf039c97/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-ph-chronic-phase 2024-10-29T20:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/fa7d30831f5b9f1f/i-m-one-of-the-first-americans-to-be-cured-of-type-1-diabetes-thanks-to-a-breakthrough-therapy 2024-10-29T20:42:54+00:00 weekly 0.7 https://trial.medpath.com/news/5f6bf3468aac12f3/fda-grants-accelerated-approval-to-asciminib-for-adult-patients-with-newly-diagnosed-ph 2024-10-29T20:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/59590b1a954bcd6f/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-29T20:21:25+00:00 weekly 0.7 https://trial.medpath.com/news/d95c73bc0d0e4758/breakthrough-new-procedure-eliminates-the-need-for-insulin-in-less-than-an-hour 2024-10-29T20:19:28+00:00 weekly 0.7 https://trial.medpath.com/news/f3e115b5305f9f69/new-device-delivers-antibiotics-directly-to-wounds-in-dogs-and-horses-dvm360 2024-10-29T20:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/15aa9bcfc7946939/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/bbb7b79bac1fbd6e/alvotech-teva-obtain-fda-nod-for-new-selarsdi-indication-drug-store-news 2024-10-29T20:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/5ddac543f8bbd215/cytexortho-gets-fda-approval-for-first-in-human-trial-of-absorbable-hip-implants 2024-10-29T19:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/db9a10d4c031b8b8/nkgen-biotech-presents-phase-1-2a-troculeucel-data-in-alzheimer-s-disease-at-the-17th 2024-10-29T19:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/58eff3c96391a960/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-phase-3-presbyopia 2024-10-29T19:22:37+00:00 weekly 0.7 https://trial.medpath.com/news/f1ae7951190781e0/neuralink-competitor-restores-vision-in-blind-patients-with-eye-implant-futurism 2024-10-29T19:21:17+00:00 weekly 0.7 https://trial.medpath.com/news/cbc6ba0d913a378b/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-for-rcc 2024-10-29T19:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/fa3f61c0a4b7937d/fda-approves-new-abuse-deterrent-alternative-for-severe-pain-management 2024-10-29T19:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/b9f280e8ae7a9ed5/immutep-quarterly-activities-report-q1-fy25-globenewswire 2024-10-29T18:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/97128850e6f007ff/a-better-drug-may-make-transplants-more-successful-time 2024-10-29T18:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/7ec3f973e54f1295/new-jama-study-shows-text-messages-can-be-ineffective-as-medication-refill-reminders 2024-10-29T18:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/77109e7aa12b92c6/fda-approves-scemblix-for-some-with-newly-diagnosed-chronic-myeloid-leukemia 2024-10-29T18:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/4ebafbb42206bf53/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of 2024-10-29T18:21:04+00:00 weekly 0.7 https://trial.medpath.com/news/87cf4712e60a8675/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-chronic-myeloid-leukemia 2024-10-29T18:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/fe270f997cfe7add/fda-approves-asciminib-in-newly-diagnosed-ph-cml-in-chronic-phase 2024-10-29T18:18:54+00:00 weekly 0.7 https://trial.medpath.com/news/04d1b5b10f66df08/asciminib-gets-accelerated-approval-for-ph-cml-oncology-nursing-news 2024-10-29T17:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/f1a17bf3ed1a0ba4/cognition-therapeutics-reports-potential-alzheimer-s-treatment-breakthrough-by-investing-com 2024-10-29T17:58:17+00:00 weekly 0.7 https://trial.medpath.com/news/d1369ffcdd64a698/micro-cap-company-is-soaring-on-phase-2-trial-update-the-globe-and-mail 2024-10-29T17:45:41+00:00 weekly 0.7 https://trial.medpath.com/news/59e4b3ac90e08d1c/shuttle-pharma-doses-first-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-biospace 2024-10-29T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/1b99eeb4e5b7d747/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/6974ff688e20850f/valbiotis-announces-interim-financial-statements-and-strategic-developments 2024-10-29T17:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/91d4bc4b7b2e900e/moderna-and-msd-begin-trial-of-mrna-4157-and-keytruda-combination-for-lung-cancer 2024-10-29T17:35:37+00:00 weekly 0.7 https://trial.medpath.com/news/52774dda38d97c15/fda-approves-abuse-deterrent-10-mg-oxycodone-hydrochloride-for-severe-pain 2024-10-29T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/69319541dfe33cf4/exploring-the-benefits-of-nab-sirolimus-in-advanced-pecoma-treatment 2024-10-29T17:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/e76a8139389a5e64/ide397-shows-early-antitumor-activity-safety-in-mtap-deletion-urothelial-cancer-and-nsclc 2024-10-29T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/dbdc78b06299d18c/well-health-and-healwell-ai-expand-clinical-trials-tipranks-com 2024-10-29T16:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/c4ad4ad18715c99d/new-test-tailors-leukemia-treatment-boosts-survival-odds-helsinki-times 2024-10-29T16:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/9ba1a7369463cdd4/j-j-to-seek-fda-approval-after-small-bore-impella-heart-pump-hits-trial-goal 2024-10-29T16:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/23244cc79cd37db4/naobios-and-sumagen-achieve-milestone-in-hiv-1-vaccine-production-contract-pharma 2024-10-29T16:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/cf0985997c100af6/recursion-advances-ai-based-c-diff-candidate-to-phase-ii 2024-10-29T16:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/e973bffc9eb8feab/distant-recurrence-risk-among-women-with-early-breast-cancer-enrolled-in-clinical-trials 2024-10-29T16:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/6c70950037eb80ce/eli-lilly-says-modified-dosing-of-its-alzheimer-s-drug-kisunla-may-be-safer-stat-news 2024-10-29T16:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/ef00723a952fbbfe/mosaic-8b-pan-sarbecovirus-vaccine-enters-development 2024-10-29T15:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/c9e50ee074288f74/start-and-fundacion-rioja-salud-to-expand-access-to-cancer-drug-trials-in-spain-yahoo 2024-10-29T15:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/1b1ea92495aadd19/start-and-fundacion-rioja-salud-to-expand-access-to-cancer-drug-trials-in-spain 2024-10-29T15:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/bb59712d31e6fe2e/j-j-to-seek-fda-approval-after-small-bore-impella-heart-pump-hits-trial-goal-medtech-dive 2024-10-29T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/5edcc80b92d151e2/psma-pet-ct-can-reveal-prostate-cancer-recurrences-before-biochemical-criteria-met 2024-10-29T15:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/fc60169bc3fee087/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T15:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/d24835ec09a10555/fda-approves-fibrin-sealant-to-control-surgical-bleeding-in-pediatric-patients 2024-10-29T15:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/f05f2bae9e6e1b37/shorla-oncology-announces-u-s-food-and-drug-administration-fda-expanded-approval 2024-10-29T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/4f32c9122de764d8/fda-grants-approval-to-oxycodone-hydrochloride-immediate-release-tablets-pharmacy-times 2024-10-29T14:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/01d71874e129d41d/fda-expands-methotrexate-indication-to-included-children-with-acute-lymphoblastic-leukemia 2024-10-29T14:59:20+00:00 weekly 0.7 https://trial.medpath.com/news/16c72eb2d880f7d3/long-term-bimekizumab-data-offer-new-hope-for-hs-management 2024-10-29T14:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/eff789cb040d1dc8/ptc-to-ask-for-fda-approval-of-vatiquinone-for-fa-by-year-s-end-friedreich-s-ataxia-news 2024-10-29T14:54:02+00:00 weekly 0.7 https://trial.medpath.com/news/782f24046da5fb6f/longeveron-r-presents-lomecel-btm-data-for-alzheimer-s-globenewswire 2024-10-29T14:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/1cbdfca1480345d3/novartis-inks-150m-molecular-glue-deal-with-monte-rosa-inside-precision-medicine 2024-10-29T14:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/cda2bf339e41d826/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T14:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/e74d3ce1906a8ec4/painchek-prepares-fda-de-novo-submission-for-smartphone-app-following-successful-us 2024-10-29T14:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/b158ebb459afbe38/gemvax-announces-topline-results-from-phase-2a-progressive-supranuclear-palsy 2024-10-29T14:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/ccb2a437aedd5ef7/novartis-presents-data-from-fabhalta-at-asn-kidney-week-2024-pharmabiz 2024-10-29T14:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/7757e869688e605b/fda-expands-approval-for-methotrexate-in-pediatric-all-pjia-indications-cancer-network 2024-10-29T14:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/4ef3484356e49e4c/lifechanging-new-cancer-therapy-kills-99-of-cancer-cells-the-brighter-side-of-news 2024-10-29T14:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/655386fedd9ac2b8/gilead-sciences-to-withdraw-sacituzumab-govitecan-bladder-cancer-approval-status 2024-10-29T14:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/9a113e0fe8c0dff4/mira-pharmaceuticals-shares-surge-40-after-ketamir-2-excels-in-gurufocus 2024-10-29T14:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/9266d12473c671ae/microbial-dynamics-and-pulmonary-immune-responses-in-covid-19-secondary-bacterial-pneumonia 2024-10-29T13:46:02+00:00 weekly 0.7 https://trial.medpath.com/news/4faa261228075dda/digital-avatar-therapy-for-distressing-voices-in-psychosis-the-phase-2-3-avatar2-trial 2024-10-29T13:43:27+00:00 weekly 0.7 https://trial.medpath.com/news/03944721918967ab/fda-clears-paragonix-kidneyvault-portable-renal-perfusion-system-massdevice 2024-10-29T13:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/0988e6afe4ca57e0/fda-expands-approval-for-jylamvo-oral-methotrexate-solution-in-all-targeted-oncology 2024-10-29T13:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/37d06c8fa8ebaa41/j-j-and-lilly-both-boast-il-23-inhibitor-efficacy-in-crohn-s-disease-yahoo-finance 2024-10-29T13:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/ba4c74bed88696e4/heartlung-technologies-receives-fda-breakthrough-status-and-marketing-authorization 2024-10-29T13:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/193f13ebbbe1210a/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T13:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/326424e8e55d0c5e/canadian-health-tech-companies-developing-ai-enhanced-clinical-trials-stockhouse 2024-10-29T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/54b878a43317d4b5/glp-1-medications-show-promise-as-first-drug-therapy-for-sleep-apnea 2024-10-29T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/c88e3c262db6fcdc/j-j-and-lilly-both-unveil-il-23-inhibitor-efficacy-in-crohn-s-disease-clinical-trials-arena 2024-10-29T13:11:26+00:00 weekly 0.7 https://trial.medpath.com/news/03b8158de7e30eb5/medidata-and-cogstate-strike-strategic-partnership-transforming-clinical-trials-in 2024-10-29T13:09:36+00:00 weekly 0.7 https://trial.medpath.com/news/aa7802974bacfa8d/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-globenewswire 2024-10-29T13:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/05f30d1d1d263a9a/fda-expands-approval-of-methotrexate-to-include-pediatric-acute-lymphoblastic-leukemia 2024-10-29T13:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/28bf1e7dc347405c/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T13:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/168fe900c078ca78/rallybio-to-begin-first-clinical-trial-for-prevention-of-rare-pregnancy-blood-disorder 2024-10-29T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/f7492e8b3753aa73/ec-approves-expanded-use-of-edurant-for-younger-paediatric-hiv-1-patients 2024-10-29T13:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/e5bf92dd5b42092f/chiesi-announces-phase-3-results-from-enzyme-replacement-study-pharmafile 2024-10-29T12:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/ae7ebc635c705f7e/eli-lilly-tells-bloomberg-approval-received-to-launch-mounjaro-in-hong-kong 2024-10-29T12:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/4380a7c6ab041f81/upcoming-fda-advisory-panel-for-icecure-s-prosense-r-marketing-authorization-receives 2024-10-29T12:49:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c02a7d034781b1b/protega-pharmaceuticals-receives-fda-approval-for-roxybondtm-oxycodone-morningstar 2024-10-29T12:48:44+00:00 weekly 0.7 https://trial.medpath.com/news/f778617cecbc1192/pathos-ai-closes-62m-oversubscribed-series-c-round-of-globenewswire 2024-10-29T12:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/900f6545d7ec1e55/protega-pharmaceuticals-receives-fda-approval-for-roxybondtm-oxycodone-pr-newswire 2024-10-29T12:37:28+00:00 weekly 0.7 https://trial.medpath.com/news/cee4d88b94bb103a/chiesi-global-rare-diseases-announces-publication-of-results-from-phase-3-bright-biospace 2024-10-29T12:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/ae4c55971edafd46/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-biospace 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/04b5574f25bfea1b/first-patient-in-bioporto-initiates-patient-enrollment-for-us-study-of-pronephro-aki-ngal 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/ace929b3cae77360/shuttle-pharma-completes-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-biospace 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/8e5dc469b02ce458/paragonix-technologies-receives-fda-510-k-clearance-for-kidneyvault-portable-renal 2024-10-29T12:33:51+00:00 weekly 0.7 https://trial.medpath.com/news/af1a1a9fc86516c6/new-therapy-after-islet-cell-transplant-shows-promise-for-people-with-type-1-diabetes 2024-10-29T12:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/3f44870f9a3038fb/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T12:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/573f5ae76ba0a155/astrazeneca-s-rare-disease-therapy-fasenra-receives-eu-approval 2024-10-29T12:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/767627a165500a82/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-globenewswire 2024-10-29T12:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/39e3afc392759b81/medidata-and-cogstate-strike-strategic-partnership-transforming-clinical-trials-in-morningstar 2024-10-29T12:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/232a5649675337ee/spero-therapeutics-gets-investor-suit-over-fda-approval-tossed-bloomberg-law-news 2024-10-29T12:13:12+00:00 weekly 0.7 https://trial.medpath.com/news/11dc8d6219add849/immatics-tcr-t-therapy-shows-good-phase-1-safety-and-survival-data-phase-3-plans-confirmed 2024-10-29T12:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/446efae19d2daeb7/spero-therapeutics-gets-investor-suit-over-fda-approval-tossed-bloomberg-law-news 2024-10-29T12:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/37c01f5797ea316d/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/819c2ad38dcb2483/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-29T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/9de7aede9f83af7d/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T12:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/b006ed7f67835a02/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T12:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/4ae0632b2340f175/immutep-quarterly-activities-report-q1-fy25-immp-stock-news 2024-10-29T12:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/42c8823637c2bdde/well-health-technologies-corp-and-healwell-ai-inc-expands-strategic-marketscreener 2024-10-29T12:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/97de048eb59f2ea4/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-with-its-fibrin 2024-10-29T12:03:17+00:00 weekly 0.7 https://trial.medpath.com/news/32e4fa76dfebdf61/ehr-data-emerges-as-critical-source-for-real-world-evidence-generation-in-drug-development 2024-10-29T11:56:51+00:00 weekly 0.7 https://trial.medpath.com/news/bbc7dbc0264d6360/briacell-therapeutics-corp-sec-10-k-report-tradingview 2024-10-29T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/963143f6d86063ae/resalis-therapeutics-gets-equity-investment-from-sanofi-european-biotechnology 2024-10-29T11:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/f6a9409e1c465d5d/harmony-biosciences-reports-strong-third-quarter-2024-financial 2024-10-29T11:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/542fd648ca56f9d4/abeona-therapeutics-r-completes-pz-cel-biologics-license-globenewswire 2024-10-29T11:40:01+00:00 weekly 0.7 https://trial.medpath.com/news/7de4d65e98bfb02e/shuttle-pharma-completes-clinical-trial-site-enrollment-for-globenewswire 2024-10-29T11:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/22b894ea541d1179/how-az-s-respiratory-wins-are-ramping-up-for-a-bigger-prize-in-copd-pharmavoice 2024-10-29T11:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/3ae9353f2fd1e647/shifting-the-ga-paradigm-ophthalmology-times 2024-10-29T11:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/0d88bdb12766c9d5/invivyd-phase-3-long-term-exploratory-clinical-efficacy-globenewswire 2024-10-29T11:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/2b7daaac398d3cd6/shorla-oncology-announces-u-s-food-and-drug-administration-fda-expanded-approval 2024-10-29T11:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/bdc496e146ad340d/sagimet-biosciences-announces-successful-completion-of-end-of-phase-2-interactions-with 2024-10-29T11:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/01fa1ef445c8f8e2/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai 2024-10-29T11:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/e84295f8e0e7fdb2/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a 2024-10-29T11:04:40+00:00 weekly 0.7 https://trial.medpath.com/news/37a3db8053bd2efd/lilly-and-j-j-face-off-in-crohn-s-disease-with-phase-iii-readouts-at-acg-2024-biospace 2024-10-29T11:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/07c1c9d921d80541/mayo-clinic-expert-highlights-evolution-of-immunotherapy-in-advanced-hodgkin-lymphoma-treatment 2024-10-29T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f17c2338addfc306/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a 2024-10-29T10:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/6b4efd9f825d8281/pentixapharm-holding-ag-us-national-cancer-institute-starts-advanced-clinical-trial-with 2024-10-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/a92ad12d95574ee7/dach-region-emerges-as-clinical-trial-hub-despite-eu-s-strict-medical-device-regulations 2024-10-29T10:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc721e2b0c03e8d9/maia-biotechnology-announces-2-44-million-private-placement-form-8-k 2024-10-29T10:21:11+00:00 weekly 0.7 https://trial.medpath.com/news/2bb2d559842b9406/shorla-oncology-announces-u-s-fda-expanded-approval-of-jylamvo-methotrexate-an-oncology-and-autoimmune-drug-for-pediatric-indications 2024-10-29T10:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/d0052fc32931dcda/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml 2024-10-29T10:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/08e25bc088fc541e/digital-rehabilitation-care-planning-for-people-with-chronic-diseases-rehapro-serve-trials 2024-10-29T09:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/3e8eb5d35d589a25/niab-scientists-working-on-next-generation-vaccine-against-leptospirosis-the-hindu 2024-10-29T09:51:56+00:00 weekly 0.7 https://trial.medpath.com/news/0c3a705e365a9ced/devyser-seeks-to-secure-fda-approval-for-ngs-test-for-kidney-transplant-monitoring 2024-10-29T09:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/0196ae7e88edb0f2/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on 2024-10-29T09:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/1006410b6e8ef9be/protega-pharmaceuticals-receives-fda-approval-for-roxybond-oxycodone-hydrochloride-immediate-release-10-mg-tablet-with-abuse-deterrent-technology-for-management-of-pain 2024-10-29T09:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/1dc68168d1b248be/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on 2024-10-29T09:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/902197284f0b8817/bprw-3-black-medical-schools-receive-funding-to-improve-clinical-trials-press-releases 2024-10-29T09:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/5632efadf5d66bdf/cinclus-pharma-agrees-with-ema-on-pediatric-study-plan-marketscreener 2024-10-29T08:37:39+00:00 weekly 0.7 https://trial.medpath.com/news/b4e44e61206f9c63/paragonix-s-kidney-vault-receives-fda-nod-for-organ-transport-bioworld 2024-10-29T08:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/def1c1c60bdc264d/novartis-raises-profit-guidance-pushes-off-myelofibrosis-drug-submission-stat-news 2024-10-29T08:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/044dc23dabf0e462/rvu120-shows-early-promise-in-r-r-metastatic-or-advanced-solid-tumors-onclive 2024-10-29T08:14:03+00:00 weekly 0.7 https://trial.medpath.com/news/33b3103dea9e3e5b/regeneration-biomedical-presents-data-on-first-cohort-from-globenewswire 2024-10-29T08:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/ed82afc8faeb8ff5/irlab-makes-progress-in-preparation-for-phase-iii-of-mesdopetam-marketscreener 2024-10-29T07:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/1a109b99a0e6f6b7/efficacy-and-safety-of-nanoparticle-albumin-bound-paclitaxel-plus-carboplatin-as-bmc-medicine 2024-10-29T07:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/d44503c09f61d9ce/first-children-vaccinated-in-new-clinical-study-seeking-to-expand-the-indication-marketscreener 2024-10-29T07:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/df48884af9fa69de/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai 2024-10-29T07:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/593103bbaa61b28b/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-29T07:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/e0c58d869c6cfe59/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-newsfile-corp 2024-10-29T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/2c6a849e0bca7b4b/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-improve-precision-in-outpatient 2024-10-29T07:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/97955ac5141b45b6/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-marketscreener 2024-10-29T06:49:53+00:00 weekly 0.7 https://trial.medpath.com/news/4115ba3a4d13c575/irlab-reports-continued-progress-ahead-of-the-mesdopetam-phase-iii-program 2024-10-29T06:40:41+00:00 weekly 0.7 https://trial.medpath.com/news/93f98069c3fab092/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-tradingview 2024-10-29T06:40:41+00:00 weekly 0.7 https://trial.medpath.com/news/5a02298ecba8ffd2/most-hae-patients-attack-free-after-ntla-2002-treatment-in-trial-angioedema-news 2024-10-29T06:40:03+00:00 weekly 0.7 https://trial.medpath.com/news/0ea9ae6673fe09ca/maze-therapeutics-reports-positive-data-from-phase-i-akd-treatment-trial 2024-10-29T06:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/65a258d7a6854d17/first-children-vaccinated-in-new-clinical-study-seeking-to-globenewswire 2024-10-29T06:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/186cb8d2b82a27a2/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-placera 2024-10-29T06:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/4fea122794cf5da6/rezatapopt-monotherapy-remains-under-study-following-discontinuation-of-combination 2024-10-29T06:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/09ad9df552c263ab/dexmedetomidine-nasal-spray-on-emergence-agitation-after-ear-nose-an-ijgm 2024-10-29T06:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/9b39ec219b9e5485/avecho-biotechnology-expands-trials-and-manufacturing-markets-insider 2024-10-29T06:20:56+00:00 weekly 0.7 https://trial.medpath.com/news/5cf618c5d90fc8ce/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of 2024-10-29T06:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/d4865aafd797eafa/an-electronic-patient-reported-outcome-symptom-monitor-the-chinese-experience-with-rapid 2024-10-29T05:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/0d3e38efebae346c/personalized-medicine-reshapes-breast-cancer-treatment-landscape-expert-highlights-multiple-approaches 2024-10-29T05:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/c675d05b4ab11cbe/merck-moderna-begin-phase-3-trial-of-mrna-4157-in-combo-with-keytruda-after-pharmabiz 2024-10-29T04:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/3ca67f78df77d3b4/new-cancer-treatment-trial-shrinks-luton-man-s-brain-tumour-by-half-after-just-weeks-of 2024-10-29T04:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/3785b312209027ae/remegen-announces-the-acceptance-of-the-marketing-application-of-telitaccept-for-stock-titan 2024-10-29T04:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/6fe92be66c5790db/dr-reddy-s-launches-bixibat-to-treat-chronic-constipation-in-india-express-pharma 2024-10-29T04:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/3b03e7e9364b590f/sheri-yang-and-michael-mitchell-awarded-2-79-million-nih-grant-to-study-new-treatment 2024-10-29T04:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/4743db44d856c835/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved 2024-10-29T03:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/dc5eebb60bfaed43/cbp-issues-warning-on-biological-material-import-violations-in-clinical-research 2024-10-29T03:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/23a40a7a023e77e9/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-29T03:43:40+00:00 weekly 0.7 https://trial.medpath.com/news/96a3b8bde155cdf3/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/644d94e66282837c/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:19:23+00:00 weekly 0.7 https://trial.medpath.com/news/222a8143089c8762/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/4814ce1bab671273/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-pr-newswire 2024-10-29T02:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/a3f1bc725b5553b2/community-based-research-sites-revolutionize-clinical-trial-accessibility-and-diversity 2024-10-29T02:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/ee5a2057186633da/tertiary-lymphoid-structures-linked-to-improved-treatment-outcomes-in-liver-cancer 2024-10-29T01:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/142db595b5067837/early-intervention-in-patients-with-asymptomatic-severe-aortic-stenosis-and-myocardial-fibrosis 2024-10-29T01:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/d7db7b8b0d64dfe0/acg-2024-j-j-data-reveals-new-crohn-s-treatment-option 2024-10-29T00:57:34+00:00 weekly 0.7 https://trial.medpath.com/news/8ef5b01cb4a83a18/moderna-brass-hit-with-investor-suit-over-rsv-shot-claims-law360 2024-10-29T00:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/236bda835a5acb34/south-korea-s-yuhan-has-690-profit-spike-on-u-s-lung-cancer-drug-sales 2024-10-29T00:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/fc4adffd85630bce/is-mdma-the-breakthrough-in-treating-post-traumatic-stress-disorder-listnr-articles 2024-10-29T00:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/deea6da4daf099f0/qol-remains-key-consideration-for-first-line-treatment-of-anemia-in-lower-risk-mds 2024-10-29T00:07:23+00:00 weekly 0.7 https://trial.medpath.com/news/5097b72ff19ffd0c/dr-reddy-s-launches-constipation-drug-in-india-the-hindu 2024-10-29T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/a52d0c479d1223f2/impella-ecp-confirmed-to-be-safe-for-high-risk-pci-is-fda-approval-next 2024-10-28T23:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/4c8c7dbe8858b12f/merck-moderna-launch-phase-iii-trial-of-v940-in-combination-with-keytruda-for-resectable 2024-10-28T23:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/9614f10767ccab2d/lilly-s-ebglyss-shows-improvement-in-phase-iiib-study-for-atopic-dermatitis 2024-10-28T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/167d7f4b0c3d8ac9/maia-biotechnology-announces-2-44-million-private-placement 2024-10-28T23:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/3fe8644669b4ddc4/tyra-biosciences-receives-ind-clearance-from-fda-to-proceed-with-phase-2-study-of 2024-10-28T23:14:27+00:00 weekly 0.7 https://trial.medpath.com/news/2ad02b4fad07c717/maia-biotechnology-announces-2-44-million-private-placement-yahoo-finance 2024-10-28T23:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/a6af78db692d83ed/maia-biotechnology-announces-2-44-million-private-placement-morningstar 2024-10-28T23:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/4386f2fbfb698536/maia-biotechnology-announces-2-44-million-private-placement-company-markets-data 2024-10-28T23:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/177ec1405b177f68/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in 2024-10-28T22:54:24+00:00 weekly 0.7 https://trial.medpath.com/news/c6cf4f239b62c32a/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney 2024-10-28T22:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/79bf921aedb2205f/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney 2024-10-28T21:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/acf463d080567863/phase-3-trial-begins-in-mrna-based-therapy-plus-keytruda-in-non-small-cell-lung-cancer 2024-10-28T21:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/d8008c225e3177be/breakthrough-iron-transport-protein-found-in-malaria-parasite-mirage-news 2024-10-28T21:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/a00da2f50470cd47/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data-for-ongoing-phase-2 2024-10-28T21:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/30b7819604d644c0/ema-official-reports-on-scientific-advice-pilots-for-high-risk-and-orphan-devices-raps 2024-10-28T20:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/c0aa205be0f9826a/novel-prostate-cancer-treatment-increases-overall-newswise 2024-10-28T20:48:39+00:00 weekly 0.7 https://trial.medpath.com/news/718dfdadfcbebd56/biotech-alert-searches-spiking-for-these-stocks-today-markets-insider 2024-10-28T20:38:14+00:00 weekly 0.7 https://trial.medpath.com/news/6f1ed89fdb0c9394/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3 2024-10-28T20:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/ff3ad55728d114b1/what-3-big-trials-mean-for-breast-cancer-practice-oncology-news-central 2024-10-28T20:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/efb44b874f68c7a0/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/4b8fcac1ac606406/merck-moderna-launch-phase-3-trial-evaluating-adjuvant-v940-keytruda-combo 2024-10-28T20:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/e1b2fb7ab2e89d84/fda-approves-new-oral-antibiotic-for-urinary-tract-infections-cidrap 2024-10-28T20:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/a0422dfd6dae3ca5/wvu-rockefeller-neuroscience-institute-receives-state-funding-to-expand-research-and 2024-10-28T20:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/39c91f5b2e6b76ae/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-after-neoadjuvant-keytruda-and-chemotherapy-in-patients-with-certain-types-of-non-small-cell-lung-cancer-nsclc 2024-10-28T19:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/a277a380daf6ef0f/ide397-shows-preliminary-efficacy-in-mtap-nsclc-and-urothelial-cancer 2024-10-28T19:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/1223c4e4745fad42/implantable-microparticles-can-deliver-two-cancer-therapies-at-once-mit-news 2024-10-28T18:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/7addb55da4748e8b/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-chronic 2024-10-28T18:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/b8296d99c45b9635/fda-oks-new-drug-for-urinary-tract-infections-webmd 2024-10-28T18:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/d7b9e100a65d9a13/syndax-pharmaceuticals-swot-analysis-stock-poised-for-growth-amid-fda-approvals 2024-10-28T18:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/65620d45868241b0/novartis-signs-global-license-agreement-with-monte-rosa-therapeutics-worth-up-to-2-1 2024-10-28T18:19:46+00:00 weekly 0.7 https://trial.medpath.com/news/5ad1edb255babe04/the-start-center-for-cancer-research-and-fundacion-rioja-salud-announce-pr-newswire 2024-10-28T18:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/9099270ac58b2dbb/monte-rosa-scores-2-1b-novartis-deal-for-molecular-glue-degraders-bioworld 2024-10-28T17:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/fed0c0e3f378aac0/mira-pharmaceuticals-formulated-shows-greater-efficacy-than-fda-approved-drug-benzinga 2024-10-28T17:54:51+00:00 weekly 0.7 https://trial.medpath.com/news/5010f90cd4cb4474/eyepoint-pharmaceuticals-reports-positive-16-week-interim-results-from-phase-2-verona 2024-10-28T17:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/45684dbea3f42430/scientists-develop-a-digital-twin-model-to-predict-cancer-treatment-responses 2024-10-28T17:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/465ffd398444cc56/rmc-9805-triggers-tumor-regressions-in-kras-g12c-mutant-pancreatic-cancer 2024-10-28T17:36:39+00:00 weekly 0.7 https://trial.medpath.com/news/6579e9fc00d5995a/omvoh-achieves-long-term-remission-symptom-improvement-for-ulcerative-colitis-crohn 2024-10-28T17:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/041d5ae2a33fcbe6/the-debate-over-the-predictive-utility-of-pd-l1-low-expression-is-ongoing-in-escc 2024-10-28T17:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/71931058a68f96f1/novartis-fabhalta-shows-promise-in-phase-3-kidney-disease-trial 2024-10-28T17:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/43a45dfeb1025b5b/ugn-102-data-published-in-journal-of-urology-as-fda-weighs-nmibc-approval 2024-10-28T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/b79978d8b0f2d147/new-study-explores-nalmefene-and-naloxone-for-reversal-of-respiratory-depression 2024-10-28T17:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/4ea60041ce7f4427/complement-inhibitors-clinical-trial-pipeline-analysis-40-globenewswire 2024-10-28T17:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/18225d7b2814dc92/investigational-fgfr3-selective-inhibitor-shows-promise-in-urothelial-cancer 2024-10-28T17:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/8dc75983023ae49d/movano-to-respond-to-fda-questions-as-part-of-eviemed-final-review-phase 2024-10-28T17:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/a4b8f30bfb6a566d/targeting-er-stress-sensor-restores-immunogenicity-of-chemotherapy-nature-reviews-immunology 2024-10-28T16:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/13cc1ffdba83efef/why-is-moderna-stock-trading-higher-on-monday-benzinga 2024-10-28T16:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/db85c026532ecb06/delta-fly-pharma-inc-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml-patients 2024-10-28T16:45:29+00:00 weekly 0.7 https://trial.medpath.com/news/57378c9ee3f06f01/fda-fast-tracks-hc-7366-in-relapsed-refractory-acute-myeloid-leukemia 2024-10-28T16:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/3e9d9d54df1d3095/yes-we-can-bridgebio-shares-positive-gene-therapy-data-in-canavan-trial 2024-10-28T16:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/4fd1ba8bc122c2ec/semaglutide-may-cut-alzheimer-s-risk-in-type-2-diabetes-inside-precision-medicine 2024-10-28T16:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/981b09ac9de7fde2/marinus-pharmaceuticals-swot-analysis-rare-epilepsy-drug-maker-s-stock-faces-pivotal-moment 2024-10-28T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/81597a6e539f0629/fda-approves-first-rsv-vaccine-for-at-risk-adults-younger-than-50-copd-news-today 2024-10-28T16:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/46304ebf7f25356e/ai-for-detection-of-diastolic-dysfunction-gains-fda-breakthrough-device-designation-healio 2024-10-28T16:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/092cc40e5cd905be/iterum-therapeutics-plc-itrm-u-s-fda-approval-of-orlynvah-call-transcript 2024-10-28T16:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/910df21a47c4f018/american-academy-of-ophthalmology-oct-18-21-healthday 2024-10-28T16:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/3a8242a3c0688be7/mmv-and-quotient-sciences-initiate-clinical-trial-for-long-acting-malaria-preventive 2024-10-28T15:52:06+00:00 weekly 0.7 https://trial.medpath.com/news/d4cfb27da8ca8c26/fda-grants-de-novo-authorisation-for-distalmotion-s-dexter-surgical-robot 2024-10-28T15:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/c013cb8525481fd5/addition-of-induction-chemotherapy-to-standard-chemoradiotherapy-in-locally-advanced 2024-10-28T15:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/de49377a37ad8c34/is-medical-cannabis-for-children-under-18-a-good-idea-university-of-cincinnati 2024-10-28T15:40:03+00:00 weekly 0.7 https://trial.medpath.com/news/5573f00baafdc479/monte-rosa-joins-with-novartis-in-molecular-glue-drug-deal-biopharma-dive 2024-10-28T15:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/6632828f1ce1c025/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T15:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/40ecc60ef27b2db2/harvard-apparatus-regenerative-technology-announces-strategic-collaboration-with-biospace 2024-10-28T15:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/7dfde60202bc14dc/bipolar-disorder-manic-depression-pipeline-assessment-2024-openpr-com 2024-10-28T15:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/6973d1b9c57b948c/immunotherapy-plus-targeted-therapy-for-anaplastic-thyroid-carcinoma-the-asco-post 2024-10-28T15:35:55+00:00 weekly 0.7 https://trial.medpath.com/news/c65aba0c17b20ee6/respiratory-syncytial-virus-pipeline-2024-clinical-trials-assessment-fda-approvals 2024-10-28T15:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/dcbff0fcf5aee522/evolved-early-avr-fails-to-help-asymptomatic-as-patients-with-fibrosis-tctmd-com 2024-10-28T15:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/d2e0f42552a2dcd3/astrazeneca-drug-approved-in-the-eu-for-rare-immune-disease 2024-10-28T15:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/c15d846cbe136613/top-stocks-to-buy-now-2-biotech-stocks-to-watch-stockmarket-com 2024-10-28T15:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/d6225698e5c593af/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T15:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/208432bcef0a3da8/bora-acquires-rare-diseases-drugmaker-pyros-pharmaceuticals 2024-10-28T15:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/d460a06f1ddd4700/large-language-model-influence-on-diagnostic-reasoning-a-randomized-clinical-trial 2024-10-28T15:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/23945e95cacb669a/with-new-diversity-guidance-ehr-data-plus-ai-will-be-critical-biopharma-dive 2024-10-28T15:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/50040ace08b1c8ed/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/ea81fb160c83f33a/uae-s-clinical-trials-space-matures-with-experience-from-covid-19 2024-10-28T15:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/6c5b6090807d6def/study-links-polygenic-scores-to-hypertension-treatment-outcomes-medical-xpress 2024-10-28T15:03:55+00:00 weekly 0.7 https://trial.medpath.com/news/0625d86ff57922d7/fda-grants-odd-status-to-mdl-101-for-lama2-cmd-treatment 2024-10-28T15:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/c70f0ed336b55584/findings-and-recommendations-of-the-moh-committee-of-inquiry-nni-ministry-of-health 2024-10-28T15:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/eb68ecb43e80c481/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-28T14:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/a4330ba8c6b7b0e9/semaglutide-may-cut-alzheimer-s-risk-in-type-2-diabetes-healthleaders-media 2024-10-28T14:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/973539771643474d/cardiol-therapeutics-initiates-phase-ii-iii-clinical-trial-for-recurrent-pericarditis 2024-10-28T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/6029560c79c8dc35/shifamed-s-adona-medical-initiates-first-in-human-interatrial-shunt-study-massdevice 2024-10-28T14:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/259ca42119379d19/primary-chemoablation-of-recurrent-low-grade-intermediate-risk-nonmuscle-invasive 2024-10-28T14:49:00+00:00 weekly 0.7 https://trial.medpath.com/news/8c28dcc28e0d3671/dr-reddy-s-launches-first-in-class-drug-to-treat-chronic-constipation-in-india 2024-10-28T14:44:40+00:00 weekly 0.7 https://trial.medpath.com/news/871dbde4ad0868ec/accord-biopharma-announces-fda-approval-of-imuldosa-ustekinumab-srlf-mondaq 2024-10-28T14:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/3c4865433cece487/christine-n-kay-md-tease-trials-show-promise-of-gildeuretinol-for-stargardt 2024-10-28T14:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/e6f7ce6b46b8524e/christine-n-kay-md-tease-trials-show-promise-of-gildeuretinol-for-stargardt-hcplive 2024-10-28T14:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/fbd0cac5d101348c/coya-therapeutics-announces-conference-call-to-report-results-from-an-investigator-biospace 2024-10-28T14:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/03862a0568499891/sparrow-pharmaceuticals-announces-completion-of-phase-2-trial-and-fda-orphan-drug 2024-10-28T14:38:50+00:00 weekly 0.7 https://trial.medpath.com/news/0cf33b8a0868f5a5/envision-trial-results-published-in-the-journal-of-urology-report-82-3-duration-of-biospace 2024-10-28T14:38:50+00:00 weekly 0.7 https://trial.medpath.com/news/e6171ddf095693fd/exploring-the-perioperative-treatment-setting-in-lung-cancer-targeted-oncology 2024-10-28T14:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/a45f05fb7ad77012/truist-holds-buy-on-biogen-shares-price-target-steady-on-complete-results-investing-com 2024-10-28T14:23:38+00:00 weekly 0.7 https://trial.medpath.com/news/754f46252eda371b/fda-approval-of-orlynvah-for-urinary-tract-infections-marks-milestone-for-iterum-paves 2024-10-28T14:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/0c67d8309ce43b7a/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-chronic 2024-10-28T14:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/2a1b06dbeea9529d/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T14:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/749c5fb011a6d889/delayed-antibody-treatment-may-improve-efficacy-of-mrna-vaccines-news-center 2024-10-28T14:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/9202328826e64287/efficacy-and-safety-of-biosimilar-ranibizumab-optimab-r-versus-in-opth 2024-10-28T14:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/1b51592abda0bcad/amneal-obtains-fda-ok-for-pyridostigmine-bromide-er-tablets-drug-store-news 2024-10-28T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/bbf3a2cbeae5f31a/rapid-blood-cancer-diagnostic-could-speed-decisions-and-save-lives-onclive 2024-10-28T14:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/f11102c54f44c2e5/collaborative-effort-to-conduct-a-study-aimed-at-improving-the-diagnosis-of-alzheimer-s-and 2024-10-28T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/d7bb66232a13a194/will-the-upcoming-trial-updates-on-elritercept-revive-kros-s-momentum-rttnews 2024-10-28T13:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/773dc604449e1249/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T13:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/92c9de5b2cd2a646/sylvester-physician-scientists-find-new-target-for-cancer-treatment-inventum 2024-10-28T13:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/4dfb9287eeb7a479/distalmotion-wins-fda-de-novo-nod-for-dexter-surgical-robot-massdevice 2024-10-28T13:31:14+00:00 weekly 0.7 https://trial.medpath.com/news/ede0dfa170d8cf25/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T13:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/01fd1ca3a7ec02ae/biocardia-completes-phase-iii-randomized-double-blind-globenewswire 2024-10-28T13:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/99750fa9cc8e8751/delfi-diagnostics-working-with-incendia-therapeutics-to-employ-advanced-treatment 2024-10-28T13:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/64efd77d578bcbde/delta-fly-pharma-inc-announces-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml 2024-10-28T13:16:44+00:00 weekly 0.7 https://trial.medpath.com/news/0cd30ae648ef4ddb/harvard-apparatus-regenerative-technology-announces-strategic-collaboration-with-stock-titan 2024-10-28T13:16:02+00:00 weekly 0.7